Patent Grant
9687864
The present invention relates generally to surface coatings and processes for making. More particularly, the invention relates to a system and method for enhancing charge of coating particles produced by rapid expansion of near-critical and supercritical solutions that improves quality of surface coatings.
A high coating density is desirable for production of continuous thin films on surfaces of finished devices following post-deposition processing steps. Nanoparticle generation and electrostatic collection (deposition) processes that produce surface coatings can suffer from poor collection efficiencies and poor coating densities that result from inefficient packing of nanoparticles. Low-density coatings are attributed to the dendritic nature of the coating. “Dendricity” as the term is used herein is a qualitative measure of the extent of particle accumulations or fibers found on, the coating. For example, a high dendricity means the coating exhibits a fuzzy or shaggy appearance upon inspection due to fibers and particle accumulations that extend from the coating surface; the coating also has a low coating density. A low dendricity means the coating is smooth and uniform upon inspection and has a high coating density. New processes are needed that can provide coatings with a low degree of dendricity, suitable for use, e.g., on medical devices and other substrates.
Provided herein is a system for electrostatic deposition of particles upon a charged substrate to form a coating on a surface of the substrate, the system comprising: an expansion nozzle that releases coating particles having a first average electric potential suspended in a gaseous phase from a near-critical or supercritical fluid that is expanded through said nozzle; and an auxiliary emitter that generates a stream of charged ions having a second average potential in an inert carrier gas; whereby said coating particles interact with the charged ions and the carrier gas to enhance a charge differential between the coating particles and the substrate.
Provided herein is a system for electrostatic deposition of particles upon a charged substrate to form a coating on a surface of the substrate, the system comprising: an expansion nozzle that releases coating particles having a first average electric potential suspended in a gaseous phase from a near-critical or supercritical fluid that is expanded through the nozzle; and an auxiliary emitter that generates a stream of charged ions having a second average electric potential in an inert carrier gas; whereby the coating particles interact with the charged ions and the carrier gas to enhance a potential differential between the coating particles and the substrate.
In some embodiments, the coating particles have a first velocity upon release of the coating particles from the expansion nozzle that is less than a second velocity of the coating particles when the coating particles impact the substrate. In some embodiments, attraction of the coating particles to the substrate is increased as compared to attraction of the coating particles to the substrate in a system without the auxiliary emitter.
In some embodiments, the first average electric potential is different than the second average electric potential. In some embodiments, an absolute value of the first average electric potential is less than an absolute value of the second average electric potential, and wherein a polarity the charged ions is the same as a polarity of the coating particles.
In some embodiments, the auxiliary emitter comprises an electrode having a tapered end that extends into a gas channel that conducts the stream of charged ions in the inert carrier gas toward the charged coating particles. In some embodiments, the auxiliary emitter further comprises a capture electrode. In some embodiments, the auxiliary emitter comprises a metal rod with a tapered tip and a delivery orifice.
In some embodiments, the substrate is positioned in a circumvolving orientation around the expansion nozzle.
In some embodiments, the substrate comprises a conductive material. In some embodiments, the substrate comprises a semi-conductive material. In some embodiments, the substrate comprises a polymeric material.
In some embodiments, the charged ions at the second electric potential are a positive corona or a negative corona positioned between the expansion nozzle and the substrate. In some embodiments, the charged ions at the second electric potential are a positive corona or a negative corona positioned between the auxiliary emitter and the substrate.
In some embodiments, the coating particles comprises at least one of: polylactic acid (PLA); poly(lactic-co-glycolic acid) (PLGA); polycaprolactone (poly(e-caprolactone)) (PCL), polyglycolide (PG) or (PGA), poly-3-hydroxybutyrate; LPLA poly(l-lactide), DLPLA poly(dl-lactide), PDO poly(dioxolane), PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid) and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof.
In some embodiments, the coating particles comprise at least one of: polyester, aliphatic polyester, polyanhydride, polyethylene, polyorthoester, polyphosphazene, polyurethane, polycarbonate urethane, aliphatic polycarbonate, silicone, a silicone containing polymer, polyolefin, polyamide, polycaprolactam, polyamide, polyvinyl alcohol, acrylic polymer, acrylate, polystyrene, epoxy, polyethers, celluiosics, expanded polytetrafluoroethylene, phosphorylcholine, polyethyleneyerphthalate, polymethylmethavrylate, poly(ethylmethacrylate/n-butylmethacrylate), parylene-C, polyethylene-co-vinyl acetate, polyalkyl methacrylates, polyalkylene-co-vinyl acetate, polyalkylene, polyalkyl siloxanes, polyhydroxyalkanoate, polyfluoroalkoxyphasphazine, poly(styrene-b-isobutylene-b-styrene), poly-butyl methacrylate, poly-byta-diene, and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof.
In some embodiments, the coating particles have a size between about 0.01 micrometers and about 10 micrometers.
In some embodiments, the second velocity is in the range from about 0.1 cm/sec to about 100 cm/sec. In some embodiments, the coating has a density on the surface in the range from about 1 volume % to about 60 volume %.
In some embodiments, the coating is a multilayer coating. In some embodiments, the substrate is a medical implant. In some embodiments, the substrate is an interventional device. In some embodiments, the substrate is a diagnostic device. In some embodiments, the substrate is a surgical tool. In some embodiments, the substrate is a stent.
In some embodiments, the coating is non-dendritic as compared to a baseline average coating thickness. In some embodiments, no coating extends more than 0.5 microns from the baseline average coating thickness. In some embodiments, no coating extends more than 1 micron from the baseline average coating thickness.
In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 0.5 microns. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 1 micron. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 2 microns following sintering of the coated substrate. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 3 microns following sintering of the coated substrate.
Provided herein is a system for enhancing charge of solid coating particles produced from expansion of a near-critical or supercritical solution for electrostatic deposition upon a charged substrate as a coating. The system is characterized by: an expansion nozzle that releases charged coating particles having a first potential suspended in a gaseous phase from a near-critical or supercritical fluid that is expanded through the expansion nozzle; and an auxiliary emitter that generates a stream of selectively charged ions having a second potential in an inert carrier gas stream. Charged coating particles interact with charged ions in the gas stream to enhance a charge differential between the charged coating particles and the substrate. The substrate is positioned within an electric field and is subject to that field, which increases the velocity at which the charged coating particles impact the substrate. The auxiliary emitter includes a metal rod electrode having a tapered end that extends into a gas channel containing a flowing inert carrier gas. The auxiliary emitter further includes a counter-electrode that operates at a potential relative to the rod electrode. The counter-electrode may be in the form of a ring, with all points on the ring being equidistant from the tapered tip. The counter electrode can be grounded or oppositely charged. A corona is generated at the pointed tip of the tapered rod, emitting a stream of charged ions. The gas channel conducts the charged ions in the inert carrier gas into the deposition enclosure, where they interact with the coating particles produced by the fluid expansion process. The substrate to be coated by the coating particles may be positioned in a circumvolving orientation around the expansion nozzle. In one embodiment, the substrate is positioned on a revolving stage or platform that provides the circumvolving orientation around the expansion nozzle. Substrates can be individually rotated clockwise or counterclockwise through a rotation of 360 degrees. The substrate can include a conductive material, a metallic material, and/or a semi-conductive material. The coating that results on the substrate has: an enhanced surface coverage, an enhanced surface coating density, and minimized dendrite formation.
Provided herein is a method for forming a coating on a surface of a substrate, comprising: establishing an electric field between the substrate and a counter electrode; producing coating particles suspended in a gaseous phase of an expanded near-critical or supercritical fluid having an first average electric potential; and contacting the coating particles with a stream of charged ions at a second average potential in an inert carrier gas to increase the charge differential between the coating particles and the substrate.
Provided herein is a method for coating a surface of a substrate with a preselected material forming a coating, comprising the steps of: establishing an electric field between the substrate and a counter electrode; producing coating particles suspended in a gaseous phase of an expanded near-critical or supercritical fluid having an first average electric potential; and contacting the coating particles with a stream of charged ions at a second average potential in an inert carrier gas to increase the potential differential between the coating particles and the substrate.
In some embodiments, the coating particles have a first velocity upon release of the coating particles from the expansion nozzle that is less than a second velocity of the coating particles when the coating particles impact the substrate. In some embodiments, attraction of the coating particles to the substrate is increased as compared to attraction of the coating particles to the substrate in a system without the auxiliary emitter. In some embodiments, the first average electric potential is different than the second average electric potential. In some embodiments, an absolute value of the first average electric potential is less than an absolute value of the second average electric potential, and wherein a polarity the charged ions is the same as a polarity of the coating particles.
In some embodiments, the second velocity is in the range from about 0.1 cm/sec to about 100 cm/sec.
In some embodiments, the coating particles have a size between about 0.01 micrometers and about 10 micrometers.
In some embodiments, the substrate has a negative polarity and an enhanced charge of the coating particles following the contacting step is a positive charge; or wherein the substrate has a positive polarity and an enhanced charge of the coating particles following the contacting step is a negative charge.
In some embodiments, the contacting step comprises forming a positive corona or forming a negative corona positioned between the expansion nozzle and the substrate. In some embodiments, the contacting step comprises forming a positive corona or forming a negative corona positioned between the auxiliary emitter and the substrate.
In some embodiments, the coating has a density on the surface from about 1 volume % to about 60 volume %.
In some embodiments, the coating particles comprise at least one of: a polymer, a drug, a biosorbable material, a protein, a peptide, and a combination thereof.
In some embodiments, the coating particles comprises at least one of: polylactic acid (PLA); poly(lactic-co-glycolic acid) (PLGA); polycaprolactone (poly(e-caprolactone)) (PCL), polyglycolide (PG) or (PGA), poly-3 hydroxybutyrate; LPLA poly(l-lactide), DLPLA poly(dl-lactide), PDO poly(dioxolane), PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid) and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof. In some embodiments, the coating on the substrate comprises polylactoglycolic acid (PLGA) at a density greater than 5 volume %.
In some embodiments, the coating particles comprise at least one of: polyester, aliphatic polyester, polyanhydride, polyethylene, polyorthoester, polyphosphazene, polyurethane, polycarbonate urethane, aliphatic polycarbonate, silicone, a silicone containing polymer, polyolefin, polyamide, polycaprolactam, polyamide, polyvinyl alcohol, acrylic polymer, acrylate, polystyrene, epoxy, polyethers, celluiosics, expanded polytetrafluoroethylene, phosphorylcholine, polyethyleneyerphthalate, polymethylmethavrylate, poly(ethylmethacrylate/n-b utylmethacrylate), parylene-C, polyethylene-co-vinyl acetate, polyalkyl methacrylates, polyalkylene-co-vinyl acetate, polyalkylene, polyalkyl siloxanes, polyhydroxyalkanoate, polyfluoroalkoxyphasphazine, poly(styrene-b-isobutylene-b-styrene), poly-butyl methacrylate, poly-byta-diene, and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof.
In some embodiments, the coating particles include a drug comprising one or more of: rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl) rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxyl)propyl-rapamycin 40-O-(6-Hydroxyl)hexyl-rapamycin 40-O-[2-(2-Hydroxyl)ethoxy]ethyl-rapamycin 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethylrapamycin, 40-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.
In some embodiments, the second velocity is in the range from about 0.1 cm/sec to about 100 cm/sec.
In some embodiments, the method further includes the step of sintering the coating at a temperature in the range from about 25° C. to about 150° C. to form a dense, thermally stable film on the surface of the substrate.
In some embodiments, the method further includes the step of sintering the coating in the presence of a solvent gas to form the dense, thermally stable film on the surface of the substrate.
In some embodiments, the producing and the contacting steps, at least, are repeated to form a multilayer film.
In some embodiments, the substrate is at least a portion of a medical implant. In some embodiments, the substrate is an interventional device. In some embodiments, the substrate is a diagnostic device. In some embodiments, the substrate is a surgical tool. In some embodiments, the substrate is a stent. In some embodiments, the substrate is a medical balloon.
In some embodiments, the coating is non-dendritic as compared to a baseline average coating thickness. In some embodiments, no coating extends more than 0.5 microns from the baseline average coating thickness. In some embodiments, no coating extends more than 1 micron from the baseline average coating thickness.
In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 0.5 microns. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 1 micron. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 2 microns following sintering of the coated substrate. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 3 microns following sintering of the coated substrate.
Provided herein is a method for coating a surface of a substrate with a preselected material, forming a coating. The method includes the steps of: establishing an electric field between the substrate and a counter electrode; producing solid solute (coating) particles from a near-critical or supercritical expansion process at an average first electric potential that are suspended in a gaseous phase of the expanded near-critical or supercritical fluid; and contacting the solid solute (coating) particles with a stream of charged ions at a second potential in an inert carrier gas to increase the charge differential between the particles and the substrate, thereby increasing the velocity at which the solute particles impact upon the substrate. The charge differential increases the attraction of the charged particles for the substrate. The solid solute particles are thus accelerated through the electric field, which increases the velocity at which the solute particles impact the surface of the substrate. High impact velocity and enhanced coating efficiency of the coating particles produce a coating on the substrate with an optimized microstructure and a low surface dendricity. The charged coating particles have a size that may be between about 0.01 micrometers and 10 micrometers. In one embodiment, the substrate includes a negative polarity and the enhanced charge of the solid solute particles is a positive enhanced charge. In another embodiment, the substrate includes a positive polarity and the enhanced charge of the solid solute particles is a negative enhanced charge. The increase in charge differential increases the velocity of the solid solute particles through an electric field that increases the force of impact of the particles against the surface of the substrate. The method further includes the step of sintering the coating that is formed during the deposition/collection process to form a thermally stable continuous film on the substrate, e.g., as detailed in U.S. Pat. No. 6,749,902, incorporated herein in its entirety. Various sintering temperatures and/or exposure to a gaseous solvent can be used. In some embodiments, sintering temperatures for forming dense, thermally stabile from the collected coating particles are selected in the range from about 25° C. to about 150° C. In one embodiment described hereafter, the invention is used to deposit biodegradable polymer and/or other coatings to surfaces that are used to produce continuous layers or films, e.g., on biomedical and/or drug-eluting devices (e.g., medical stents), and/or portions of medical devices. The coatings can also be applied to other medical devices and components including, e.g., medical implant devices such as, e.g., stents, medical balloons, and other biomedical devices.
Provided herein is a coating on a surface of a substrate produced by any of the methods described herein. Provided herein is a coating on a surface of a substrate produced by any of the systems described herein.
The final film from the coating can be a single layer film or a multilayer film. For example, the process steps can be repeated one or more times and with various materials to form a multilayer film on the surface of the substrate. In one embodiment, the medical device is a stent. In another embodiment, the substrate is a conductive metal stent. In yet another embodiment, the substrate is a non-conductive polymer medical balloon. The coating particles include materials that consist of: polymers, drugs, biosorbable materials, proteins, peptides, and combinations of these materials. In various embodiments, impact velocities at which the charged coating particles impact the substrate are from about 0.1 cm/sec to about 100 cm/sec. In some embodiments, the polymer that forms the solute particles is a biosorbable organic polymer and the supercritical fluid solvent includes a fluoropropane. In one embodiment, the coating is a polylactoglycolic acid (PLGA) coating that includes a coating density greater than (>) about 5 volume %.
In one embodiment, the charged ions at the selected potential are a positive corona positioned between an emission location and a deposition location of the substrate. In another embodiment, the charged ions at the selected potential are a negative corona positioned between an emission location and a deposition location of the substrate.
While the invention is described herein with reference to high-density coatings deposited onto medical device surfaces, in particular, stent surfaces, the invention is not limited thereto. All substrates as will be envisioned by those of ordinary skill in the art in view of the disclosure are within the scope of the invention. No limitations are intended.
The invention is a system and method for enhancing electrostatic deposition of charged particles upon a charged substrate forming nanoparticle coatings. The invention improves collection efficiency, microstructure, and density of coatings, which minimizes dendricity of the coating on the selected substrate. Solid solute (coating) particles are generated from near-critical and supercritical solutions by a process of Rapid Expansion of (near-critical or) Supercritical Solutions, known as the RESS process.
The term “e-RESS” refers to the process for forming coatings by electrostatically collecting RESS expansion particles.
The term “near-critical fluid” as used herein means a fluid that is a gas at standard temperature and pressure (i.e., STP) and presently is at a pressure and temperature below the critical point, and where the fluid density exceeds the critical density (ρc).
The term “supercritical fluid” means a fluid at a temperature and pressure above its critical point. The invention finds application in the generation and efficient collection of these particles producing coatings with a low dendricity, e.g., for deposition on medical stents and other devices.
Various aspects of the RESS process are detailed in U.S. Pat. Nos. 4,582,731; 4,734,227; 4,734,451; 6,749,902; and 6,756,084 assigned to Battelle Memorial Institute, which patents are incorporated herein in their entirety.
Solid solute particles produced by the invention are governed by various electrostatic effects, the fundamentals of which are detailed, e.g., in “Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles” (William C. Hinds, Author, John Wiley & Sons, Inc., New York, N.Y., Ch. 15, Electrical Properties, pp. 284-314, 1982).
Embodiments of the invention comprise an auxiliary emitter and/or a process of using the same that enhances charge of RESS-generated coating particles, which improves the collection efficiency and deposition. The auxiliary emitter delivers a corona that enhances the charge of the solid solute particles. The term “corona” as used herein means an emission of charged ions accompanied by ionization of the surrounding atmosphere. Both positive and negative coronas may be used with the invention, as detailed further herein. Fundamentals of electrostatic processes including formation of coronal discharges are detailed, e.g., in the “Encyclopedia of Electrical and Electronics Engineering” (John Wiley & Sons, Inc., John G. Webster (Editor), Volume 7, Electrostatic Processes, 1999, pp. 15-39), which reference is incorporated herein. The enhanced charge further increases the velocity of impact of the coating particles on a selected substrate, improving the collection efficiency on the coating surface. The term “coating” as used herein refers to one or more layers of electrostatically-deposited coating particles on a substrate or surface.
Embodiments of the invention enhance the charge and collection efficiency of the coating particles that improves the microstructure, weight, and/or the coating density, which minimizes formation of dendrites during the deposition process. Thus, the quality of the particle coating on the substrate is enhanced. When sintered, the coating particles subsequently coalesce to form a continuous, uniform, and thermally stable film.
The invention thus produces high-density coatings that when deposited on various substrate surfaces are amenable to sintering into high quality films. The term “high density” as used herein means an electrostatic near-critical or supercritical solution-expanded (RESS) coating on a substrate having a coating density of from about 1 volume % to about 60 volume %, and the coating has a low-surface dendricity rating at or below 1 as measured, e.g., from a cross-sectional view of the coating and the substrate by scanning-electron micrograph (SEM). The term “volume %” is defined herein as the ratio of the volume of solids divided by the total volume times 100.
Another definition of a coating that is “high density” as described herein (or systems comprising such coatings, or processes producing such coating) includes a test for packing density of the coating in which the coating is determined to be non-dendritic as compared to a baseline average coating thickness for substrates coated at the same settings. That is, for a particular coating process set of settings for a given substrate (before sintering), a baseline average coating thickness is determined by determining and averaging coating thickness measurements at multiple locations (e.g. 3 or more, 5 or more, 9 or more, 10 or more) and for several substrates (if possible). The baseline average coating thickness and/or measurement of any coated substrate prior to sintering may be done, for example, by SEM or another visualization method having the ability to measure and visualize to the coating with accuracy, confidence and/or reliability.
Once the average is determined, for coatings on substrates coated at such settings can be compared to the average coating thickness for these settings. Multiple locations of the substrate may be tested to ensure the appropriate confidence and/or reliability. In some embodiments, a “non-dendritic”coating has no coating that extends more than 1 micron from the average coating thickness. In some embodiments, a “non-dendritic” coating has no coating that extends more than 0.5 microns from the average coating thickness. In some embodiments, a “non-dendritic” coating has no coating that extends more than 1.5 microns from the average coating thickness. In some embodiments, a “non-dendritic” coating has no coating that extends more than 2 microns from the average coating thickness. In some embodiments, a “dendritic” coating has coating that extends more than 0.5 microns from the average coating thickness. In some embodiments, a “dendritic” coating has coating that extends more than 1 micron from the average coating thickness. In some embodiments, a “dendritic” coating has coating that extends more than 1.5 microns from the average coating thickness. In some embodiments, a “dendritic” coating has coating that extends more than 2 microns from the average coating thickness.
In some embodiments, the number of sample locations on the coated substrate is chosen to ensure 90% confidence and 90% reliability that the coating is non-dendritic. In some embodiments, the number of sample locations on the coated substrate is chosen to ensure 95% confidence and 90% reliability that the coating is non-dendritic. In some embodiments, the number of sample locations on the coated substrate is chosen to ensure 95% confidence and 95% reliability that the coating is non-dendritic. In some embodiments, the number of sample locations on the coated substrate is chosen to ensure 99% confidence and 95% reliability that the coating is non-dendritic. In some embodiments, the number of sample locations on the coated substrate is chosen to ensure 99% confidence and 99% reliability that the coating is non-dendritic.
In some embodiments, at least 9 sample locations are reviewed, three at about a first end, 3 at about the center of the substrate, and 3 at about a second end of a substrate, and if none of the locations exceed the specification (e.g., greater than 2 microns from the average, greater than 1.5 microns from the average, greater than 1 micron from the average, or greater than 0.5 microns from the average), then the coating is non-dendritic. In some embodiments, the entire substrate is reviewed and compared to the average coating thickness to ensure the coating is non-dendritic.
In some embodiments, each substrate is compared to its own average coating thickness, and not that of other substrates processed at the same or similar coating process settings.
In embodiments where multiple coating layers are created on a substrate, with a sintering step following each coating, this test may be performed following any particular coating step just prior to sintering. The variability in coating thickness of a previous sintered layer may (or may not) be accounted for in the calculations such that a second and/or subsequent layer may allow for greater variation from the average coating thickness and still be considered “non-dendritic.”
In some embodiments, a coated substrate (before sintering) is non-dendritic if there is no surface irregularity greater than 0.5 microns. That is, a measurement from the base (or trough) of the coating to a peak of the coating does not exceed 0.5 microns. In some embodiments, a coated substrate (before sintering) is non-dendritic if there is no surface irregularity greater than 1 micron. That is, a measurement from the base (or trough) of the coating to a peak of the coating does not exceed 1 micron. In some embodiments, a coated substrate (before sintering) is non-dendritic if there is no surface irregularity greater than 1.5 microns. That is, a measurement from the base (or trough) of the coating to a peak of the coating does not exceed 1.5 microns. In some embodiments, a coated substrate (before sintering) is non-dendritic if there is no surface irregularity greater than 2 microns. That is, a measurement from the base (or trough) of the coating to a peak of the coating does not exceed 2 microns. The entire substrate does not require review and testing for these to be met, rather, as noted above, a sampling resulting in a particular confidence/reliability (for example, 90%/90%, 90%/95%, 95%/95%, 99%/95%, and/or 99%/99%) is sufficient.
In some embodiments, a coated substrate (post sintering) is non-dendritic if there is no surface irregularity greater than 2 microns. That is, a measurement from the base (or trough) of the coating to a peak of the coating does not exceed 2 microns if measured after sintering. In some embodiments, a coated substrate (post sintering) is non-dendritic if there is no surface irregularity greater than 2.5 microns. That is, a measurement from the base (or trough) of the coating to a peak of the coating does not exceed 2.5 microns if measured after sintering. In some embodiments, a coated substrate (post sintering) is non-dendritic if there is no surface irregularity greater than 3 microns. That is, a measurement from the base (or trough) of the coating to a peak of the coating does not exceed 3 microns if measured after sintering. The entire substrate does not require review and testing for these to be met, rather, as noted above, a sampling resulting in a particular confidence/reliability (for example, 90%/90%, 90%/95%, 95%/95%, 99%/95%, and/or 99%/99%) is sufficient. In embodiments where multiple coating layers are created on a substrate, with a sintering step following each coating, this confidence/reliability testing may be performed following any particular sintering step. No limitations are intended.
For example,
The term “sintering” used herein refers to processes—with or without the presence of a gas-phase solvent to reduce sintering temperature—whereby e-RESS particles initially deposited as a coating coalesce, forming a continuous dense, thermally stable film on a substrate. Coatings can be sintered by the process of heat-sintering at selected temperatures described herein or alternatively by gas-sintering in the presence of a solvent gas or supercritical fluid as detailed, e.g., in U.S. Pat. No. 6,749,902, which patent is incorporated herein in its entirety. The term “film” as used herein refers to a continuous layer produced on the surface after sintering of an e-RESS-generated coating.
Embodiments of the invention find application in producing coatings of devices including, e.g., medical stents that are coated, e.g., with time-release drugs for time-release drug applications. These and other enhancements and applications are described further herein. While the process of coating in accordance with the invention will be described in reference to the coating of medical stent devices, it should be strictly understood that the invention is not limited thereto. The person or ordinary skill in the art will recognize that the invention can be used to coat a variety of substrates for various applications. All coatings as will be produced by those of ordinary skill in view of the disclosure are within the scope of the invention. No limitations are intended.
In the instant embodiment, collector 16 is positioned within auxiliary body 18. Auxiliary body 18 inserts into, and couples snugly with, base portion 20, e.g., via two (2) O-rings 19 composed of, e.g., a fluoroelastomer (e.g., VITON®, DuPont, Wilmington, Del., USA), or another suitable material positioned between auxiliary body 18 and base portion 20. Base portion 20 is secured to the deposition vessel (
Provided herein is a system for electrostatic deposition of particles upon a charged substrate to form a coating on a surface of the substrate, the system comprising: an expansion nozzle that releases coating particles having a first average electric potential suspended in a gaseous phase from a near-critical or supercritical fluid that is expanded through the nozzle; and an auxiliary emitter that generates a stream of charged ions having a second average potential in an inert carrier gas; whereby the coating particles interact with the charged ions and the carrier gas to enhance a charge differential between the coating particles and the substrate.
Provided herein is a system for electrostatic deposition of particles upon a charged substrate to form a coating on a surface of the substrate, the system comprising: an expansion nozzle that releases coating particles having a first average electric potential suspended in a gaseous phase from a near-critical or supercritical fluid that is expanded through the nozzle; and an auxiliary emitter that generates a stream of charged ions having a second average electric potential in an inert carrier gas; whereby the coating particles interact with the charged ions and the carrier gas to enhance a potential differential between the coating particles and the substrate.
In some embodiments, the coating particles have a first velocity upon release of the coating particles from the expansion nozzle that is less than a second velocity of the coating particles when the coating particles impact the substrate. In some embodiments, attraction of the coating particles to the substrate is increased as compared to attraction of the coating particles to the substrate in a system without the auxiliary emitter.
In some embodiments, the first average electric potential is different than the second average electric potential. In some embodiments, an absolute value of the first average electric potential is less than an absolute value of the second average electric potential, and wherein a polarity the charged ions is the same as a polarity of the coating particles.
In some embodiments, the auxiliary emitter comprises an electrode having a tapered end that extends into a gas channel that conducts the stream of charged ions in the inert carrier gas toward the charged coating particles. In some embodiments, the auxiliary emitter further comprises a capture electrode. In some embodiments, the auxiliary emitter comprises a metal rod with a tapered tip and a delivery orifice.
In some embodiments, the substrate is positioned in a circumvolving orientation around the expansion nozzle.
In some embodiments, the substrate comprises a conductive material. In some embodiments, the substrate comprises a semi-conductive material. In some embodiments, the substrate comprises a polymeric material.
In some embodiments, the charged ions at the second electric potential are a positive corona or a negative corona positioned between the expansion nozzle and the substrate. In some embodiments, the charged ions at the second electric potential are a positive corona or a negative corona positioned between the auxiliary emitter and the substrate.
In some embodiments, the coating particles comprises at least one of: polylactic acid (PLA); poly(lactic-co-glycolic acid) (PLGA); polycaprolactone (poly(e-caprolactone)) (PGL), polyglycolide (PG) or (PGA), poly-3-hydroxybutyrate; LPLA poly(l-lactide), DLPLA poly(dl-lactide), PDO poly(dioxolane), PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid) and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof.
In some embodiments, the coating particles comprise at least one of: polyester, aliphatic polyester, polyanhydride, polyethylene, polyorthoester, polyphosphazene, polyurethane, polycarbonate urethane, aliphatic polycarbonate, silicone, a silicone containing polymer, polyolefin, polyamide, polycaprolactam, polyamide, polyvinyl alcohol, acrylic polymer, acrylate, polystyrene, epoxy, polyethers, celluiosics, expanded polytetrafluoroethylene, phosphorylcholine, polyethyleneyerphthalate, polymethylmethavrylate, poly(ethylmethacrylate/n-butylmethacrylate), parylene C, polyethylene-co-vinyl acetate, polyalkyl methacrylates, polyalkylene-co-vinyl acetate, polyalkylene, polyalkyl siloxanes, polyhydroxyalkanoate, polyfluoroalkoxyphasphazine, poly(styrene-b-isobutylene-b-styrene), poly-butyl methacrylate, poly-byta-diene, and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof.
In some embodiments, the coating particles include a drug comprising one or more of: rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxyl)propyl-rapamycin 40-O-(6-Hydroxyl)hexyl-rapamycin 40-O-[2-(2-Hydroxyl)ethoxy]ethyl-rapamycin 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxyl)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethylrapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolirnus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.
In some embodiments, the coating particles have a size between about 0.01 micrometers and about 10 micrometers.
In some embodiments, the second velocity is in the range from about 0.1 cm/sec to about 100 cm/sec. In some embodiments, the coating has a density on the surface in the range from about 1 volume % to about 60 volume %.
In some embodiments, the coating is a multilayer coating. In some embodiments, the substrate is a medical implant. In some embodiments, the substrate is an interventional device. In some embodiments, the substrate is a diagnostic device. In some embodiments, the substrate is a surgical tool. In some embodiments, the substrate is a stent.
Medical implants may comprise any implant for insertion into the body of a human or animal subject, including but not limited to stents (e.g., coronary stents, vascular stents including peripheral stents and graft stents, urinary tract stents, urethral/prostatic stents, rectal stent, oesophageal stent, biliary stent, pancreatic stent), electrodes, catheters, leads, implantable pacemaker, cardioverter or defibrillator housings, joints, screws, rods, ophthalmic implants, femoral pins, bone plates, grafts, anastomotic devices, perivascular wraps, sutures, staples, shunts for hydrocephalus, dialysis grafts, colostomy bag attachment devices, ear drainage tubes, leads for pace makers and implantable cardioverters and defibrillators, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds, various types of dressings (e.g., wound dressings), bone substitutes, intraluminal devices, vascular supports, etc. In some embodiments, the substrate is selected from the group consisting of: stents, joints, screws, rods, pins, plates, staples, shunts, clamps, clips, sutures, suture anchors, electrodes, catheters, leads, grafts, dressings, pacemakers, pacemaker housings, cardioverters, cardioverter housings, defibrillators, defibrillator housings, prostheses, ear drainage tubes, ophthalmic implants, orthopedic devices, vertebral disks, bone substitutes, anastomotic devices, perivascular wraps, colostomy bag attachment devices, hemostatic barriers, vascular implants, vascular supports, tissue adhesives, tissue sealants, tissue scaffolds and intraluminal devices.
In some embodiments, the substrate is an interventional device. An “interventional device” as used herein refers to any device for insertion into the body of a human or animal subject, which may or may not be left behind (implanted) for any length of time including, but not limited to, angioplasty balloons, cutting balloons.
In some embodiments, the substrate is a diagnostic device. A “diagnostic device” as used herein refers to any device for insertion into the body of a human or animal subject in order to diagnose a condition, disease or other of the patient, or in order to assess a function or state of the body of the human or animal subject, which may or may not be left behind (implanted) for any length of time.
In some embodiments, the substrate is a surgical tool. A “surgical tool” as used herein refers to a tool used in a medical procedure that may be inserted into (or touch) the body of a human or animal subject in order to assist or participate in that medical procedure.
In some embodiments, the coating is non-dendritic as compared to a baseline average coating thickness. In some embodiments, no coating extends more than 0.5 microns from the baseline average coating thickness. In some embodiments, no coating extends more than 1 micron from the baseline average coating thickness.
In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 0.5 microns. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 1 micron. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 2 microns following sintering of the coated substrate. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 3 microns following sintering of the coated substrate.
Provided herein is a process for forming a coating on a surface of a substrate, comprising: establishing an electric field between the substrate and a counter electrode; producing coating particles suspended in a gaseous phase of an expanded near-critical or supercritical fluid having an first average electric potential; and contacting the coating particles with a stream of charged ions at a second average potential in an inert carrier gas to increase the charge differential between the coating particles and the substrate.
Provided herein is a method for coating a surface of a substrate with a preselected material forming a coating, comprising the steps of: establishing an electric field between the substrate and a counter electrode; producing coating particles suspended in a gaseous phase of an expanded near-critical or supercritical fluid having an first average electric potential; and contacting the coating particles with a stream of charged ions at a second average potential in an inert carrier gas to increase the potential differential between the coating particles and the substrate.
In some embodiments, the coating particles have a first velocity upon release of the coating particles from the expansion nozzle that is less than a second velocity of the coating particles when the coating particles impact the substrate. In some embodiments, attraction of the coating particles to the substrate is increased as compared to attraction of the coating particles to the substrate in a system without the auxiliary emitter. In some embodiments, the first average electric potential is different than the second average electric potential. In some embodiments, an absolute value of the first average electric potential is less than an absolute value of the second average electric potential, and wherein a polarity the charged ions is the same as a polarity of the coating particles.
In some embodiments, the coating particles have a size between about 0.01 micrometers and about 10 micrometers.
In some embodiments, the substrate has a negative polarity and an enhanced charge of the coating particles following the contacting step is a positive charge; or wherein the substrate has a positive polarity and an enhanced charge of the coating particles following the contacting step is a negative charge.
In some embodiments, the contacting step comprises forming a positive corona or forming a negative corona positioned between the expansion nozzle and the substrate. In some embodiments, the contacting step comprises forming a positive corona or forming a negative corona positioned between the auxiliary emitter and the substrate
In some embodiments, the coating has a density on the surface from about 1 volume % to about 60 volume %.
In some embodiments, the coating particles comprises at least one of: a polymer, a drug, a biosorbable material, a protein, a peptide, and a combination thereof.
In some embodiments, the coating particles comprises at least one of: polylactic acid (PLA); poly(lactic-co-glycolic acid) (PLGA); polycaprolactone (poly(e-caprolactone)) (PCL), polyglycolide (PG) or (PGA), poly-3-hydroxybutyrate; LPLA poly(l-lactide), DLPLA poly(dl-lactide), PDO poly(dioxolane), PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid) and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof. In some embodiments, the coating on the substrate comprises polylactoglycolic acid (PLGA) at a density greater than 5 volume %.
In some embodiments, the coating particles polyester, aliphatic polyester, polyanhydride, polyethylene, polyorthoester, polyphosphazene, polyurethane, polycarbonate urethane, aliphatic polycarbonate, silicone, a silicone containing polymer, polyolefin, polyamide, polycaprolactam, polyamide, polyvinyl alcohol, acrylic polymer, acrylate, polystyrene, epoxy, polyethers, celluiosics, expanded polytetrafluoroethylene, phosphorylcholine, polyethyleneyerphthalate, polymethylmethavrylate, poly(ethylmethacrylate/n-butylmethacrylate), parylene-C, polyethylene-co-vinyl acetate, polyalkyl methacrylates, polyalkylene-co-vinyl acetate, polyalkylene, polyalkyl siloxanes, polyhydroxyalkanoate, polyfluoroalkoxyphasphazine, poly(styrene-b-isobutylene-b-styrene), poly-butyl methacrylate, poly-byta-diene, and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof.
In some embodiments, the coating particles include a drug comprising one or more of: rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxyl)propyl-rapamycin 40-O-(6-Hydroxyl)hexyl-rapamycin 40-O-[2-(2-Hydroxyl)ethoxy]ethyl-rapamycin 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxyl)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethylrapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.
In some embodiments, the method further includes the step of sintering the coating at a temperature in the range from about 25° C. to about 150° C. to form a dense, thermally stable film on the surface of the substrate.
In some embodiments, the method further includes the step of sintering the coating in the presence of a solvent gas to form the dense, thermally stable film on the surface of the substrate.
In some embodiments, the producing and the contacting steps, at least, are repeated to form a multilayer film.
In some embodiments, the substrate is at least a portion of a medical implant. In some embodiments, the substrate is an interventional device. In some embodiments, the substrate is a diagnostic device. In some embodiments, the substrate is a surgical tool. In some embodiments, the substrate is a stent. In some embodiments, the substrate is a medical balloon.
Medical implants may comprise any implant for insertion into the body of a human or animal subject, including but not limited to stents (e.g., coronary stents, vascular stents including peripheral stents and graft stents, urinary tract stents, urethral/prostatic stents, rectal stent, oesophageal stent, biliary stent, pancreatic stent), electrodes, catheters, leads, implantable pacemaker, cardioverter or defibrillator housings, joints, screws, rods, ophthalmic implants, femoral pins, bone plates, grafts, anastomotic devices, perivascular wraps, sutures, staples, shunts for hydrocephalus, dialysis grafts, colostomy bag attachment devices, ear drainage tubes, leads for pace makers and implantable cardioverters and defibrillators, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds, various types of dressings (e.g., wound dressings), bone substitutes, intraluminal devices, vascular supports, etc. In some embodiments, the substrate is selected from the group consisting of: stents, joints, screws, rods, pins, plates, staples, shunts, clamps, clips, sutures, suture anchors, electrodes, catheters, leads, grafts, dressings, pacemakers, pacemaker housings, cardioverters, cardioverter housings, defibrillators, defibrillator housings, prostheses, ear drainage tubes, ophthalmic implants, orthopedic devices, vertebral disks, bone substitutes, anastomotic devices, perivascular wraps, colostomy bag attachment devices, hemostatic barriers, vascular implants, vascular supports, tissue adhesives, tissue sealants, tissue scaffolds and intraluminal devices.
In some embodiments, the substrate is an interventional device. An “interventional device” as used herein refers to any device for insertion into the body of a human or animal subject, which may or may not be left behind (implanted) for any length of time including, but not limited to, angioplasty balloons, cutting balloons.
In some embodiments, the substrate is a diagnostic device. A “diagnostic device” as used herein refers to any device for insertion into the body of a human or animal subject in order to diagnose a condition, disease or other of the patient, or in order to assess a function or state of the body of the human or animal subject, which may or may not be left behind (implanted) for any length of time.
In some embodiments, the substrate is a surgical tool. A “surgical tool” as used herein refers to a tool used in a medical procedure that may be inserted into (or touch) the body of a human or animal subject in order to assist or participate in that medical procedure.
In some embodiments, the coating is non-dendritic as compared to a baseline average coating thickness. In some embodiments, no coating extends more than 0.5 microns from the baseline average coating thickness. In some embodiments, no coating extends more than 1 micron from the baseline average coating thickness.
In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 0.5 microns. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 1 micron. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 2 microns following sintering of the coated substrate. In some embodiments, the coating is non-dendritic such that there is no surface irregularity of the coating greater than 3 microns following sintering of the coated substrate.
Charged coating particles used in some embodiments have a size (cross-sectional diameter) between about 10 nm (0.01 μm) and 10 μm. More particularly, coating particles have a size selected between about 10 nm (0.01 μm) and 2 μm.
Velocities of spherical particles in an electrical field (E) carrying maximum charge (q) can be determined from equations detailed, e.g., in “Charging of Materials and Transport of Charged Particles” (Wiley Encyclopedia of Electrical and Electronics Engineering, John G. Webster (Editor), Volume 7, 1999, John Wiley & Sons, Inc., pages 20-24), and “Properties, Behavior, and Measurement of Airborne Particles” (Aerosol Technology, William C. Hinds, 1982, John Wiley & Sons, Inc., pages 284-314), which references are incorporated herein. In particular, the electrostatic force (F) on a particle in an electric field (E) is given by Equation [1], as follows:
F=qE [1]
Here, (q) is the electric charge [SI units: Coulombs] on the particle in the electric field (E) [SI units: Newtons per Coulomb (N·C−1)], which experiences an electrostatic force (F).
A particle also experiences a viscous drag force (Fd) in an enclosure gas, which is given by Equation [2], as follows:
Fd=6πμRV [2]
Here, (μ) is the dynamic (absolute) viscosity of the selected gas, [e.g., as listed in “Viscosity of Gases”, CRC Handbook of Chemistry and Physics, 71st ed., CRC Press, Inc., 1990-1991, page 6-140, incorporated herein] at the selected gas temperature and pressure [SI units: Pascal seconds (Pa·s), where 1 μPa·s=10−5 poise; (R) is the radius of the particle (SI units: meters); and (V) is the particle terminal velocity [SI units: meters per second, (m·s−1)]. Viscosities of pure gases can vary by as much as a factor of 5 depending upon the gas type. Viscosities of refrigerant gases (e.g., fluorocarbon refrigerants) can be determined using a corresponding states method detailed, e.g., by Klein et al. [in Int. J. Refrigeration 20: 208-217, 1997, incorporated herein] over a temperature range from about −31.2° C. to 226.9° C. and pressures up to about 600 atm. Viscosities of mixed gases can be determined using Chapman-Enskog theory detailed, e.g., in [“The Properties of Gases and Liquids”, 5th ed., 2001, McGraw-Hill, Chapter 9, pages 9.1-9.51, incorporated herein], which viscosities are non-linear functions of the mole fractions of each pure gas. An exemplary e-RESS solvent used herein comprising fluoropropane refrigerant (e.g., R-236ea, Dyneon, Oakdale, Minn., USA) has a typical viscosity [at a pressure of 1 bar (15 psia), and temperature of 300K] of about −11.02 μPa·sec; nitrogen (N2) gas used as a typical carrier gas for the auxiliary emitter of the invention has a viscosity [at a pressure of 1 bar (15 psia), and temperature of 300K] of about −17.89 μPa·sec. Viscosity of an exemplary mixed gas [R-236ea and N2] (see Example 1) was estimated at −14.5 μPa·sec. The e-RESS solvent gas [R-236ea] demonstrated a viscosity about 40% lower than the N2 carrier gas in the enclosure chamber.
The terminal velocity (V) of charged particles in an electric field (E) can thus be determined by calculation by equating the electrostatic force (F) and the viscous drag force (Fd) exerted on a particle moving through a gas, as given by Equation [3]:
Maximum terminal velocities for particles may also be determined from reference tables known in the art that include data based on the maximum possible charge on a particle and the maximum potentials achievable based on gas breakdown potentials in a selected gas.
Terminal velocities of particles released in the RESS expansion plume depend at least in part on the diameter of the particles produced. For example, coating particles having a size (diameter) of about 0.2 μm have an expected terminal (impact) velocity of from about 0.1 cm/sec to about 1 cm/sec [see, e.g., Table 4, “Charging of Materials and Transport of Charged Particles”, Wiley Encyclopedia of Electrical and Electronics Engineering, Volume 7, 1999, John G. Webster (Editor), John Wiley & Sons, Inc., page 23]. Coating particles with a size of about 2 μm have an expected terminal (impact) velocity of about 1 cm/sec to about 10 cm/sec, but velocities are not limited thereto. For example, in various embodiments, charged coating particles will have expected terminal (impact) velocities at least from about 0.1 cm/sec to about 100 cm/sec. Thus, no limitations are intended.
Coatings produced by of some embodiments can be deposited to various substrates and devices, including, e.g., medical devices and other components, e.g., for use in biomedical applications. Substrates can comprise materials including, but not limited to, e.g., conductive materials, semi-conductive materials, polymeric materials, and other selected materials. In various embodiments, coatings can be applied to medical stent devices. In other embodiments, substrates can be at least a portion of a medical device, e.g., a medical balloon, e.g., a non-conductive polymer balloon. All applications as will be considered by those of skill in the art in view of the disclosure are within the scope of the invention. No limitations are intended.
Coating particles prepared by some embodiments can include various materials selected from, e.g., polymers, drugs, biosorbable materials, bioactive proteins and peptides, as well as combinations of these materials. These materials find use in coatings that are applied to, e.g., medical devices (e.g., medical balloons) and medical implant devices (e.g., drug-eluting stents), but are not limited thereto. Choice for near-critical or supercritical fluid is based on the solubility of the selected solute(s) of interest, which is not limited.
Polymers used in conjunction in some embodiments include, but are not limited to, e.g., polylactoglycolic acid (PLGA); polyethylene vinyl acetate (PEVA); poly(butyl methacrylate) (PBMA); perfluorooctanoic acid (PFOA); tetrafluoroethylene (TFE); hexafluoropropylene (HFP); polylactic acid (PLA); polyglycolic acid (PGA), including combinations of these polymers. Other polymers include various mixtures of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride (e.g., THV) at varying molecular ratios (e.g., 1:1:1).
Biosorbable polymers used in conjunction in some embodiments include, but are not limited to, e.g., polylactic acid (PLA); poly(lactic-co-glycolic acid) (PLGA); polycaprolactone (poly(e-caprolactone)) (PCL), polyglycolide (PG) or (PGA), poly-3-hydroxybutyrate; LPLA poly(l-lactide), DLPLA poly(dl-lactide), PDO poly(dioxolane), PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid) and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof.
Durable (biostable) polymers used in some embodiments include, but are not limited to, e.g., polyester, aliphatic polyester, polyanhydride, polyethylene, polyorthoester, polyphosphazene, polyurethane, polycarbonate urethane, aliphatic polycarbonate, silicone, a silicone containing polymer, polyolefin, polyamide, polycaprolactam, polyamide, polyvinyl alcohol, acrylic polymer, acrylate, polystyrene, epoxy, polyethers, celluiosics, expanded polytetrafluoroethylene, phosphorylcholine, polyethyleneyerphthalate, polymethylmethavrylate, poly(ethylmethacrylate/n-butylmethacrylate), parylene C, polyethylene-co-vinyl acetate, polyalkyl methacrylates, polyalkylene-co-vinyl acetate, polyalkylene, polyalkyl siloxanes, polyhydroxyalkanoate, polyfluoroalkoxyphasphazine, poly(styrene-b-isobutylene-b-styrene), poly-butyl methacrylate, poly-byta-diene, and blends, combinations, homopolymers, condensation polymers, alternating, block, dendritic, crosslinked, and copolymers thereof. Other polymers selected for use can include polymers to which drugs are chemically (e.g., ionically and/or covalently) attached or otherwise mixed, including, but not limited to, e.g., heparin-containing polymers (HCP).
Drugs used in embodiments described herein include, but are not limited to, e.g., antibiotics (e.g., Rapamycin [CAS No. 53123-88-9], LC Laboratories, Woburn, Mass., USA, anticoagulants (e.g., Heparin [CAS No. 9005-49-6]; antithrombotic agents (e.g., clopidogrel); antiplatelet drugs (e.g., aspirin); immunosuppressive drugs; antiproliferative drugs; chemotherapeutic agents (e.g., paclitaxel also known by the trade name TAXOL® [CAS No. 33069-62-4], Bristol-Myers Squibb Co., New York, N.Y., USA) and/or a prodrug, a derivative, an analog, a hydrate, an ester, and/or a salt thereof).
Antibiotics include, but are not limited to, e.g., arnikacin, amoxicillin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, tobramycin, geldanamycin, herbimycin, carbacephem (loracarbef), ertapenem, doripenem, imipenem, cefadroxil, cefazolin, cefalotin, cephalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftobiprole, clarithromycin, clavulanic acid, clindamycin, teicoplanin, azithromycin, dirithromycin, erythromycin, troleandomycin, telithromycin, aztreonam, ampicillin, azlocillin, bacampicillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, meticillin, nafcillin, norfloxacin, oxacillin, penicillin-G, penicillin-V, piperacillin, pvampicillin, pivmecillinam, ticarcillin, bacitracin, colistin, polymyxin-B, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, afenide, prontosil, sulfacetamide, sulfamethizole, sulfanilimide, sulfamethoxazole, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole, demeclocycline, doxycycline, oxytetracycline, tetracycline, arsphenamine, chloramphenicol, lincomycin, ethambutol, fosfomycin, furazolidone, isoniazid, linezolid, mupirocin, nitrofurantoin, platensimycin, pyrazinamide, quinupristin/dalfopristin, rifampin, thiamphenicol, rifampicin, minocycline, sultamicillin, sulbactam, sulphonamides, mitomycin, spectinomycin, spiramycin, roxithromycin, and meropenem.
Antibiotics can also be grouped into classes of related drugs, for example, aminoglycosides (e.g., amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin, tobramycin), ansamycins (e.g., geldanamycin, herbimycin), carbacephem (loracarbef) carbapenems (e.g., ertapenem, doripenem, imipenem, meropenem), first generation cephalosporins (e.g., cefadroxil, cefazolin, cefalotin, cefalexin), second generation cephalosporins (e.g., cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime), third generation cephalosporins (e.g., cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone), fourth generation cephalosporins (e.g., cefepime), fifth generation cephalosporins (e.g., ceftobiprole), glycopeptides (e.g., teicoplanin, vancomycin), macrolides (e.g., azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin), monobactams (e.g., aztreonam), penicillins (e.g., amoxicillin, ampicillin, aziocillin, bacampicillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, meticillin, nafcillin, oxacillin, penicillins-G and -V, piperacillin, pvampicillin, pivmecillinam, ticarcillin), polypeptides (e.g., bacitracin, colistin, polymyxin-B), quinolones (e.g., ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, trovafloxacin), sulfonamides (e.g., afenide, prontosil, sulfacetamide, sulfamethizole, sulfanilimide, sulfasalazine, sulfamethoxazole, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole), tetracyclines (e.g., demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline).
Anti-thrombotic agents (e.g., clopidogrel) are contemplated for use in the methods and devices described herein. Use of anti-platelet drugs (e.g., aspirin), for example, to prevent platelet binding to exposed collagen, is contemplated for anti-restenotic or anti-thrombotic therapy. Anti-platelet agents include “GpIIb/IIIa inhibitors” (e.g., abciximab, eptifibatide, tirofiban, RheoPro) and “ADP receptor blockers” (prasugrel, clopidogrel, ticlopidine). Particularly useful for local therapy are dipyridamole, which has local vascular effects that improve endothelial function (e.g., by causing local release of t-PA, that will break up clots or prevent clot formation) and reduce the likelihood of platelets and inflammatory cells binding to damaged endothelium, and cAMP phosphodiesterase inhibitors, e.g., cilostazol, that could bind to receptors on either injured endothelial cells or bound and injured platelets to prevent further platelet binding.
Chemotherapeutic agents include, but are not limited to, e.g., angiostatin, DNA topoisomerase, endostatin, genistein, ornithine decarboxylase inhibitors, chiormethine, meiphalan, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine (BCNU), streptozocin, 6-mercaptopurine, 6-thioguanine, Deoxyco-formycin, IFN-α, 17α-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate, testolactone, megestrolacetate, methylprednisolone, methyl-testosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, estramustine, medroxyprogesteroneacetate, flutamide, zoladex, mitotane, hexamethylmelamine, indolyl-3-glyoxylic acid derivatives, (e.g., indibulin), doxorubicin and idarubicin, plicamycin (mithramycin) and mitomycin, mechlorethamine, cyclophosphamide analogs, trazenes—dacarbazinine (DTIC), pentostatin and 2-chlorodeoxyadenosine, letrozole, camptothecin (and derivatives), navelbine, erlotinib, capecitabine, acivicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, ambomycin, ametantrone acetate, anthramycin, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bisnafide, bisnafide dimesylate, bizelesin, bropirimine, cactinomycin, calusterone, carbetimer, carubicin hydrochloride, carzelesin, cedefingol, celecoxib (COX-2 inhibitor), cirolemycin, crisnatol mesylate, decitabine, dexormaplatin, dezaguanine mesylate, diaziquone, duazomycin, edatrexate, eflomithine, elsamitrucin, enloplatin, enpromate, epipropidine, erbulozole, etanidazole, etoprine, flurocitabine, fosquidone, lometrexol, losoxantrone hydrochloride, masoprocol, maytansine, megestrol acetate, melengestrol acetate, metoprine, meturedepa, mitindomide, mitocarcin, mitocromin, mitogillin, mitomalcin, mitosper, mycophenolic acid, nocodazole, nogalamycin, ormaplatin, oxisuran, pegaspargase, peliomycin, pentamustine, perfosfamide, piposulfan, plomestane, porfimer sodium, porfiromycin, puromycin, pyrazofurin, riboprine, safingol, simtrazene, sparfosate sodium, spiromustine, spiroplatin, streptonigrin, sulofenur, tecogalan sodium, taxotere, tegafur, teloxantrone hydrochloride, temoporfin, thiamiprine, tirapazamine, trestolone acetate, triciribine phosphate, trimetrexate glucuronate, tubulozole hydrochloride, uracil mustard, uredepa, verteporfin, vinepidine sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine tartrate, vinrosidine sulfate, zeniplatin, zinostatin, 20-epi-1,25 dihydroxyvitamin-D3, 5-ethynyluracil, acylfulvene, adecypenol, ALL-TK antagonists, ambamustine, amidox, amifostine, aminolevulinic acid, amrubicin, anagrelide, andrographolide, antagonist-D, antagonist-G, antarelix, anti-dorsalizing morphogenetic protein-1, antiandrogen, antiestrogen, estrogen agonist, apurinic acid, ara-CDP-DL-PTBA, arginine deaminase, asulacrine, atamestane, atrimustine, axinastatin-1, axinastatin-2, axinastatin-3, azasetron, azatoxin, azatyrosine, baccatin III derivatives, balanol, BCR/ABL antagonists, benzochlorins, benzoylstaurosporine, beta lactam derivatives, beta-alethine, betaclamycin-B, betulinic acid, bFGF inhibitor, bisaziridinylspermine, bistratene-A, breflate, buthionine sulfoximine, calcipotriol, calphostin-C, carboxamide-amino-triazole, carboxyamidotriazole, CaRest M3, CARN 700, cartilage derived inhibitor, casein kinase inhibitors (ICOS), castanospermine, cecropin B, cetrorelix, chloroquinoxaline sulfonamide, cicaprost, cis-porphyrin, clomifene analogues, clotrimazole, collismycin-A, collismycin-B, combretastatin-A4, combretastatin analogue, conagenin, crambescidin-816, cryptophycin-8, cryptophycin-A derivatives, curacin-A, cyclopentanthraquinones, cycloplatam, cypemycin, cytolytic factor, cytostatin, dacliximab, dehydrodidemnin B, dexamethasone, dexifosfamide, dexrazoxane, dexverapamil, didemnin-B, didox, diethylnorspermine, dihydro-5-azacytidine, dihydrotaxol, 9-, dioxamycin, docosanol, dolasetron, dronabinol, duocarmycin-SA, ebselen, ecomustine, edelfosine, edrecolomab, elemene, emitefur, estramustine analogue, filgrastim, flavopiridol, flezelastine, fluasterone, fluorodaunorunicin hydrochloride, forfenimex, gadolinium texaphyrin, galocitabine, gelatinase inhibitors, glutathione inhibitors, hepsulfam, heregulin, hexamethylene bisacetamide, hypericin, ibandronic acid, idramantone, ilomastat, imatinib (e.g., Gleevec), imiquimod, immunostimulant peptides, insulin-like growth factor-1 receptor inhibitor, interferon agonists, interferons, interleukins, iobenguane, iododoxorubicin, ipomeanol, 4-, iroplact, irsogladine, isobengazole, isohomohalicondrin-B, itasetron, jasplakinolide, kahalalide-F, lamellarin-N triacetate, leinamycin, lenograstim, lentinan sulfate, leptolstatin, leukemia inhibiting factor, leukocyte alpha interferon, leuprolide+estrogen+progesterone, linear polyamine analogue, lipophilic disaccharide peptide, lipophilic platinum compounds, lissoclinamide-7, lobaplatin, lombricine, loxoribine, lurtotecan, lutetium texaphyrin, lysofylline, lytic peptides, maitansine, mannostatin-A, marimastat, maspin, matrilysin inhibitors, matrix metalloproteinase inhibitors, meterelin, methioninase, metoclopramide, MIF inhibitor, mifepristone, miltefosine, mirimostim, mitoguazone, mitotoxin fibroblast growth factor-saporin, mofarotene, molgramostim, Erbitux, human chorionic gonadotrophin, monophosphoryl lipid A+myobacterium cell wall sk, mustard anticancer agent, mycaperoxide-B, mycobacterial cell wall extract, myriaporone, N-acetyldinaline, N-substituted benzamides, nagrestip, naloxone+pentazocine, napavin, naphterpin, nartograstim, nedaplatin, nemorubicin, neridronic acid, nisamycin, nitric oxide modulators, nitroxide antioxidant, nitrullyn, oblimersen (Genasense), O6-benzylguanine, okicenone, onapristone, ondansetron, oracin, oral cytokine inducer, paclitaxel analogues and derivatives, palauamine, palmitoylrhizoxin, pamidronic acid, panaxytriol, panomifene, parabactin, peldesine, pentosan polysulfate sodium, pentrozole, perflubron, perillyl alcohol, phenazinomycin, phenylacetate, phosphatase inhibitors, picibanil, pilocarpine hydrochloride, placetin-A, placetin-B, plasminogen activator inhibitor, platinum complex, platinum compounds, platinum-triamine complex, propyl bis-acridone, prostaglandin-J2, proteasome inhibitors, protein A-based immune modulator, protein kinase-C inhibitors, microalgal, pyrazoloacridine, pyridoxylated hemoglobin polyoxyethylene conjugate, raf antagonists, raltitrexed, ramosetron, ras farnesyl protein transferase inhibitors, ras-GAP inhibitor, retelliptine demethylated, rhenium Re-186 etidronate, ribozymes, RII retinamide, rohitukine, romurtide, roquinimex, rubiginone-B1, ruboxyl, saintopin, SarCNU, sarcophytol A, sargramostim, Sdi-1 mimetics, senescence derived inhibitor-1, signal transduction inhibitors, sizofiran, sobuzoxane, sodium borocaptate, solverol, somatomedin binding protein, sonermin, sparfosic acid, spicamycin-D, splenopentin, spongistatin-1, squalamine, stipiamide, stromelysin inhibitors, sulfinosine, superactive vasoactive intestinal peptide antagonist, suradista, suramin, swainsonine, tallimustine, tazarotene, tellurapyrylium, telomerase inhibitors, tetrachlorodecaoxide, tetrazomine, thiocoraline, thrombopoietin, thrombopoietin mimetic, thymalfasin, thymopoietin receptor agonist, thymotrinan, thyroid stimulating hormone, tin ethyl etiopurpurin, titanocene bichloride, topsentin, translation inhibitors, tretinoin, triacetyluridine, tropisetron, turosteride, ubenimex, urogenital sinus-derived growth inhibitory factor, variolin-B, velaresol, veramine, verdins, vinxaltine, vitaxin, zanoterone, zilascorb, zinostatin stimalamer, acanthifolic acid, aminothiadiazole, anastrozole, bicalutamide, brequinar sodium, capecitabine, carmofur, Ciba-Geigy CGP-30694, cladribine, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, cytarabine ocfosfate, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co. EX-015, fazarabine, floxuridine, fludarabine, fludarabine phosphate, N-(2′-furanidyl)-5-fluorouracil, Daiichi Seiyaku FO-152, 5-FU-fibrinogen, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES, norspermidine, nolvadex, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, stearate, Takeda TAC-788, thioguanine, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, tyrosine protein kinase inhibitors, Taiho UFT, uricytin, Shionogi 254-5, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine (BiCNU), Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, dacarbazine, Degussa D-19-384, Sumimoto DACHP(Myr)2, diphenyispiromustine, diplatinum cytostatic, Chugai DWA-2114R, ITI E09, elmustine, Erbamont FCE-24517, estramustine phosphate sodium, etoposide phosphate, fotemustine, Unimed G-6-M, Chinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, lomustine, mafosfamide, mitolactol, mycophenolate, Nippon Kayaku NK-121, NCI NSC-264395, NCI NSC-342215, oxaliplatin, Upjohn PCNU, prednimustine, Prater PTT-119, ranimustine, semustine, SmithKline SK&F-101772, thiotepa, Yakult Honsha SN-22, spiromus-tine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, tetraplatin and trimelamol, Taiho 4181-A, aclarubicin, actinomycin-D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY-26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycin sulfate, bryostatin-1, Taiho C-1027, calichemycin, chromoximycin, dactinomycin, daunorubicin, Kyowa Hakko DC-102, Kyowa Hakko DC-79, Kyowa Hakko DC-88A, Kyowa Hakko DC89-A1, Kyowa Hakko DC92-B, ditrisarubicin B, Shionogi DOB-41, doxorubicin, doxorubicin-fibrinogen, elsamicin-A, epirubicin, erbstatin, esorubicin, esperamicin-A1, esperamicin-Alb, Erbamont FCE-21954, Fujisawa FK-973, fostriecin, Fujisawa FR-900482, glidobactin, gregatin-A, grincamycin, herbimycin, idarubicin, illudins, kazusamycin, kesarirhodins, Kyowa Hakko KM-5539, Kirin Brewery KRN-8602, Kyowa Hakko KT-5432, Kyowa Hakko KT-5594, Kyowa Hakko KT-6149, American Cyanamid LL-D49194, Meiji Seika ME 2303, menogaril, mitomycin, mitomycin analogues, mitoxantrone, SmithKline M-TAG, neoenactin, Nippon Kayaku NK-313, Nippon Kayaku NKT-01, SRI International NSC-357704, oxalysine, oxaunomycin, peplomycin, pilatin, pirarubicin, porothramycin, pyrindamycin A, Tobishi RA-I, rapamycin, rhizoxin, rodorubicin, sibanomicin, siwenmycin, Sumitomo SM-5887, Snow Brand SN-706, Snow Brand SN-07, sorangicin-A, sparsomycin, SS Pharmaceutical SS-21020, SS Pharmaceutical SS-7313B, SS Pharmaceutical SS-9816B, steffimycin B, Taiho 4181-2, talisomycin, Takeda TAN-868A, terpentecin, thrazine, tricrozarin A, Upjohn U-73975, Kyowa Hakko UCN-10028A, Fujisawa WF-3405, Yoshitomi Y-25024, zorubicin, 5-fluorouracil (5-FU), the peroxidate oxidation product of inosine, adenosine, or cytidine with methanol or ethanol, cytosine arabinoside (also referred to as Cytarabin, araC, and Cytosar), 5-Azacytidine, 2-Fluoroadenosine-5′-phosphate (Fludara, also referred to as FaraA), 2-Chlorodeoxyadenosine, Abarelix, Abbott A-84861, Abiraterone acetate, Aminoglutethimide, Asta Medica AN-207, Antide, Chugai AG-041R, Avorelin, aseranox, Sensus B2036-PEG, buserelin, BTG CB-7598, BTG CB-7630, Casodex, cetrolix, clastroban, clodronate disodium, Cosudex, Rotta Research CR-1505, cytadren, crinone, deslorelin, droloxifene, dutasteride, Elimina, Laval University EM-800, Laval University EM-652, epitiostanol, epristeride, Mediolanum EP-23904, EntreMed 2-ME, exemestane, fadrozole, finasteride, formestane, Pharmacia & Upjohn FCE-24304, ganirelix, goserelin, Shire gonadorelin agonist, Glaxo Wellcome GW-5638, Hoechst Marion Roussel Hoe-766, NCI hCG, idoxifene, isocordoin, Zeneca ICI-182780, Zeneca ICI-118630, Tulane University J015X, Schering Ag J96, ketanserin, lanreotide, Milkhaus LDI-200, letrozol, leuprolide, leuprorelin, liarozole, lisuride hydrogen maleate, loxiglumide, mepitiostane, Ligand Pharmaceuticals LG-1127, LG-1447, LG-2293, LG-2527, LG-2716, Bone Care International LR-103, Lilly LY-326315, Lilly LY-353381-HCl, Lilly LY-326391, Lilly LY-353381, Lilly LY-357489, miproxifene phosphate, Orion Pharma MPV-2213ad, Tulane University MZ-4-71, nafarelin, nilutamide, Snow Brand NKS01, Azko Nobel ORG-31710, Azko Nobel ORG-31806, orimeten, orimetene, orimetine, ormeloxifene, osaterone, Smithkline Beecham SKB-105657, Tokyo University OSW-1, Peptech PTL-03001, Pharmacia & Upjohn PNU-156765, quinagolide, ramorelix, Raloxifene, statin, sandostatin LAR, Shionogi S-10364, Novartis SMT-487, somavert, somatostatin, tamoxifen, tamoxifen methiodide, teverelix, toremifene, triptorelin, TT-232, vapreotide, vorozole, Yamanouchi YM-116, Yamanouchi YM-511, Yamanouchi YM-55208, Yamanouchi YM-53789, Schering AG ZK-1911703, Schering AG ZK-230211, and Zeneca ZD-182780, alpha-carotene, alpha-difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti-neoplaston-A10, antineoplaston-A2, antineoplaston-A3, antineoplaston-A5, antineoplaston-AS2-1, Henkel-APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-23015, bisantrene, Bristo-Myers BMY-40481, Vestar boron-10, bromofosfamide, Wellcome BW-502, Wellcome BW-773, calcium carbonate, Calcet, Calci-Chew, Calci-Mix, Roxane calcium carbonate tablets, caracemide, carmethizole hydrochloride, Ajinomoto CDAF, chlorsulfaquinoxalone, Chemes CHX-2053, Chemex CHX-100, Wamer-Lambert CI-921, Warner-Lambert CI-937, Warner-Lambert CI-941, Warner-Lambert CI-958, clanfenur, claviridenone, ICN compound 1259, ICN compound 4711, Contracan, Cell Pathways CP-461, Yakult Honsha CPT-11, crisnatol, curaderm, cytochalasin B, cytarabine, cytocytin, Merz D-609, DABIS maleate, datelliptinium, DFMO, didemnin-B, dihaematoporphyrin ether, dihydrolenperone dinaline, distamycin, Toyo Pharmar DM-341, Toyo Pharmar DM-75, Daiichi Seiyaku DN-9693, docetaxel, Encore Pharmaceuticals E7869, elliprabin, elliptinium acetate, Tsumura EPMTC, ergotamine, etoposide, etretinate, Eulexin, Cell Pathways Exisulind (sulindac sulphone or CP-246), fenretinide, Florical, Fujisawa FR-57704, gallium nitrate, gemcitabine, genkwadaphnin, Gerimed, Chugai GLA-43, Glaxo GR-63178, grifolan NMF-5N, hexadecyiphosphocholine, Green Cross HO-221, homoharringtonine, hydroxyurea, BTG ICRF-187, ilmofosine, irinotecan, isoglutamine, isotretinoin, Otsuka JI-36, Ramot K-477, ketoconazole, Otsuak K-76COONa, Kureha Chemical K-AM, MECT Corp KI-8110, American Cyanamid L-623, leucovorin, levamisole, leukoregulin, lonidamine, Lundbeck LU-23-112, Lilly LY-186641, Materna, NCI (US) MAP, marycin, Merrel Dow MDL-27048, Medco MEDR-340, megestrol, merbarone, merocyanine derivatives, methylanilinoacridine, Molecular Genetics MGI-136, minactivin, mitonafide, mitoquidone, Monocal, mopidamol, motretinide, Zenyaku Kogyo MST-16, Mylanta, N-(retinoyl)amino acids, Nilandron, Nisshin Flour Milling N-021, N-acylated-dehydroalanines, nafazatrom, Taisho NCU-190, Nephro-Calci tablets, nocodazole derivative, Normosang, NCI NSC-145813, NCI NSC-361456, NCI NSC-604782, NCI NSC-95580, octreotide, Ono ONO-112, oquizanocine, Akzo Org-10172, paclitaxel, pancratistatin, pazelliptine, Warner-Lambert PD-111707, Wamer-Lambert PD-115934, Warner-Lambert PD-131141, Pierre Fabre PE-1001, ICRT peptide-D, piroxantrone, polyhaematoporphyrin, polypreic acid, Efamol porphyrin, probimane, procarbazine, proglumide, Invitron protease nexin I, Tobishi RA-700, razoxane, retinoids, R-flurbiprofen (Encore Pharmaceuticals), Sandostatin, Sapporo Breweries RBS, restrictin-P, retelliptine, retinoic acid, Rhone-Poulenc RP-49532, Rhone-Poulenc RP-56976, Scherring-Plough SC-57050, Scherring-Plough SC-57068, selenium (selenite and selenomethionine), SmithKline SK&F-104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm SP-10094, spatol, spirocyclopropane derivatives, spirogermanium, Unimed, SS Pharmaceutical SS-554, strypoldinone, Stypoldione, Suntory SUN 0237, Suntory SUN 2071, Sugen SU-101, Sugen SU-5416, Sugen SU-6668, sulindac, sulindac sulfone, superoxide dismutase, Toyama T-506, Toyama T-680, taxol, Teijin TEI-0303, teniposide, thaliblastine, Eastman Kodak TJB-29, tocotrienol, Topostin, Teijin TT-82, Kyowa Hakko UCN-01, Kyowa Hakko UCN-1028, ukrain, Eastman Kodak USB-006, vinblastine, vinblastine sulfate, vincristine, vincristine sulfate, vindesine, vindesine sulfate, vinestramide, vinorelbine, vintriptol, vinzolidine, withanolides, Yamanouchi YM-534, Zileuton, ursodeoxycholic acid, Zanosar.
Drugs used in some embodiments described herein include, but are not limited to, e.g., an immunosuppressive drug such as a macrolide immunosuppressive drug, which may comprise one or more of rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxyl)propyl-rapamycin 40-O-(6-Hydroxyl)hexyl-rapamycin 40-O-[2-(2-Hydroxyl)ethoxy]ethyl-rapamycin 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxyl)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethylrapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.
Drugs used in embodiments described herein include, but are not limited to, e.g., Acarbose, acetylsalicylic acid, acyclovir, allopurinol, alprostadil, prostaglandins, amantadine, ambroxol, amlodipine, S-aminosalicylic acid, amitriptyline, atenolol, azathioprine, balsalazide, beclomethasone, betahistine, bezafibrate, diazepam and diazepam derivatives, budesonide, bufexamac, buprenorphine, methadone, calcium salts, potassium salts, magnesium salts, candesartan, carbamazepine, captopril, cetirizine, chenodeoxycholic acid, theophylline and theophylline derivatives, trypsins, cimetidine, clobutinol, clonidine, cotrimoxazole, codeine, caffeine, vitamin D and derivatives of vitamin D, colestyramine, cromoglicic acid, coumarin and coumarin derivatives, cysteine, ciclosporin, cyproterone, cytabarine, dapiprazole, desogestrel, desonide, dihydralazine, diltiazem, ergot alkaloids, dimenhydrinate, dimethyl sulphoxide, dimeticone, domperidone and domperidan derivatives, dopamine, doxazosin, doxylamine, benzodiazepines, diclofenac, desipramine, econazole, ACE inhibitors, enalapril, ephedrine, epinephrine, epoetin and epoetin derivatives, morphinans, calcium antagonists, modafinil, orlistat, peptide antibiotics, phenytoin, riluzoles, risedronate, sildenafil, topiramate, estrogen, progestogen and progestogen derivatives, testosterone derivatives, androgen and androgen derivatives, ethenzamide, etofenamate, etofibrate, fenofibrate, etofylline, famciclovir, famotidine, felodipine, fentanyl, fenticonazole, gyrase inhibitors, fluconazole, fluarizine, fluoxetine, flurbiprofen, ibuprofen, fluvastatin, follitropin, formoterol, fosfomicin, furosemide, fusidic acid, gallopamil, ganciclovir, gemfibrozil, ginkgo, Saint John's wort, glibenclamide, urea derivatives as oral antidiabetics, glucagon, glucosamine and glucosamine derivatives, giutathione, glycerol and glycerol derivatives, hypothalamus hormones, guanethidine, halofantrine, haloperidol, heparin (and derivatives), hyaluronic acid, hydralazine, hydrochlorothiazide (and derivatives), salicylates, hydroxyzine, imipramine, indometacin, indoramine, insulin, iodine and iodine derivatives, isoconazole, isoprenaline, glucitol and glucitol derivatives, itraconazole, ketoprofen, ketotifen, lacidipine, lansoprazole, levodopa, levomethadone, thyroid hormones, lipoic acid (and derivatives), lisinopril, lisuride, lofepramine, loperamide, loratadine, maprotiline, mebendazole, mebeverine, meclozine, mefenamic acid, mefloquine, meloxicam, mepindolol, meprobamate, mesalazine, mesuximide, metamizole, metformin, methylphenidate, metixene, metoprolol, metronidazole, mianserin, miconazole, minoxidil, misoprostol, mizolastine, moexipril, morphine and morphine derivatives, evening primrose, nalbuphine, naloxone, tilidine, naproxen, narcotine, natamycin, neostigmine, nicergoline, nicethamide, nifedipine, niflumic acid, nimodipine, nimorazole, nimustine, nisoldipine, adrenaline and adrenaline derivatives, novamine sulfone, noscapine, nystatin, olanzapine, olsalazine, omeprazole, omoconazole, oxaceprol, oxiconazole, oxymetazoline, pantoprazole, paracetamol (acetaminophen), paroxetine, penciclovir, pentazocine, pentifylline, pentoxifylline, perphenazine, pethidine, plant extracts, phenazone, pheniramine, barbituric acid derivatives, phenylbutazone, pimozide, pindolol, piperazine, piracetam, pirenzepine, piribedil, piroxicam, pramipexole, pravastatin, prazosin, procaine, promazine, propiverine, propranolol, propyphenazone, protionamide, proxyphylline, quetiapine, quinapril, quinaprilat, ramipril, ranitidine, reproterol, reserpine, ribavirin, risperidone, ritonavir, ropinirole, roxatidine, ruscogenin, rutoside (and derivatives), sabadilla, salbutamol, salmeterol, scopolamine, selegiline, sertaconazole, sertindole, sertralion, silicates, simvastatin, sitosterol, sotalol, spaglumic acid, spirapril, spironolactone, stavudine, streptomycin, sucralfate, sufentanil, sulfasalazine, sulpiride, sultiam, sumatriptan, suxamethonium chloride, tacrine, tacrolimus, taliolol, taurolidine, temazepam, tenoxicam, terazosin, terbinafine, terbutaline, terfenadine, terlipres sin, tertatolol, teryzoline, theobromine, butizine, thiamazole, phenothiazines, tiagabine, tiapride, propionic acid derivatives, ticlopidine, timolol, tinidazole, tioconazole, tioguanine, tioxolone, tiropramide, tizanidine, tolazoline, tolbutamide, tolcapone, tolnaftate, tolperisone, topotecan, torasemide, tramadol, tramazoline, trandolapril, tranylcypromine, trapidil, trazodone, triamcinolone derivatives, triamterene, trifluperidol, trifluridine, trimipramine, tripelennamine, triprolidine, trifosfamide, tromantadine trometamol, tropalpin, troxerutine, tulobuterol, tyramine, tyrothricin, urapidil, valaciclovir, valproic acid, vancomycin, vecuronium chloride, Viagra, venlafaxine, verapamil, vidarabine, vigabatrin, viloazine, vincamine, vinpocetine, viquidil, warfarin, xantinol nicotinate, xipamide, zafirlukast, zalcitabine, zidovudine, zolmitriptan, zolpidem, zoplicone, zotipine, amphotericin B, caspofungin, voriconazole, resveratrol, PARP-1 inhibitors (including imidazoquinolinone, imidazpyridine, and isoquinolindione, tissue plasminogen activator (tPA), melagatran, lanoteplase, reteplase, staphylokinase, streptokinase, tenecteplase, urokinase, abciximab (ReoPro), eptifibatide, tirofiban, prasugrel, clopidogrel, dipyridamole, cilostazol, VEGF, heparan sulfate, chondroitin sulfate, elongated “RGD” peptide binding domain, CD34 antibodies, cerivastatin, etorvastatin, losartan, valartan, erythropoietin, rosiglitazone, pioglitazone, mutant protein Apo A1 Milano, adiponectin, (NOS) gene therapy, glucagon-like peptide 1, atorvastatin, and atrial natriuretic peptide (ANP), lidocaine, tetracaine, dibucaine, hyssop, ginger, turmeric, Amica montana, helenalin, cannabichromene, rofecoxib, hyaluronidase, and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.
For example, coatings on medical devices can include drugs used in time-release drug applications. Proteins may be coated according to these methods and coatings described herein may comprise proteins. Peptides may be coated according to these methods and coatings described herein may comprise peptides.
In exemplary tests of the coating process, coating particles were generated by expansion of a near-critical or a supercritical solution prepared using a hydrofluorcarbon solvent, (e.g., fluoropropane R-236ea, Dyneon, Oakdale, Minn., USA) that further contained a biosorbable polymer used in biomedical applications [e.g., a 50:50 poly(DL-lactide-co-glycolide)] (Catalog No. B6010-2P), available commercially (LACTEL® Absorbable Polymers, a division of Durect, Corp., Pelham, Ala., USA). The supercritical solution was expanded and delivered through the expansion nozzle (
Provided herein is a coating on a surface of a substrate produced by any of the methods described herein. Provided herein is a coating on a surface of a substrate produced by any of the systems described herein.
In addition to single layer films, multi-layer films can also be produced by in some embodiments, e.g., by depositing coating particles made of various materials in a serial or sequential fashion to a selected substrate, e.g., a medical device. For example, in one process, coating particles comprising various single materials (e.g., A, B, C) can form multi-layer films of the form A-B-C, including combinations of these layers (e.g., A-B-A-B-C, A-B-C-A-B-C, C-B-A-A-B-C), and various multiples of these film combinations. In other processes, multi-layer films can be prepared, e.g., by depositing coating particles that include more than one material, e.g., a drug (D) and a polymer (P) carrier in a single particle of the form (DP). No limitations are intended. In exemplary tests, 3-layer films and 5-layer films were prepared that included a polymer (P) and a Drug (D), producing films of the form P-D-P and P-D-P-D-P. Films can be formed by depositing the coating particles for each layer sequentially, and then sintering. Alternatively, coating particles for any one layer can be deposited, followed by a sintering step to form the multi-layer film. Tests showed film quality is essentially identical.
Thickness and coating materials are principal parameters for producing coatings suitable, e.g., for medical applications. Film thickness on a substrate is controlled by factors including, but not limited to, e.g., expansion solution concentration, delivery pressure, exposure times, and deposition cycles that deposits coating particles to the substrate. Coating thickness is further controlled such that biosorption of the polymer, drug, and/or other materials delivered in the coating to the substrate is suitable for the intended application. Thickness of any one e-RESS film layer on a substrate may be selected in the range from about 0.1 μm to about 100 μm. For biomedical applications and devices, individual e-RESS film layers may be selected in the range from about 5 μm to about 10 μm. Because thickness will depend on the intended application, no limitations are intended by the exemplary or noted ranges. Quality of the coatings can be inspected, e.g., spectroscopically.
Total weight of solutes delivered through the expansion nozzle during the coating process is given by Equation [4], as follows:
Weight of coating solute deposited onto a selected substrate (e.g., a medical stent) is given by Equation [5], as follows:
Total Wt. Collected (g)=Σ1N[(Wt(after)−Wt(before)] [5]
In Equation [5], (N) is the number of substrates or stents. The coating weight is represented as the total weight of solute (e.g., polymer, drug, etc.) collected on all substrates (e.g., stents) present in the deposition vessel divided by the total number of substrates (e.g., stents).
“Coating efficiency” as used herein means the quantity of coating particles that are actually incorporated into a coating deposited on a surface of a substrate (e.g., stent). The coating efficiency normalized per surface is given by Equation [6], as follows:
A coating efficiency of 100% represents the condition in which all of the coating particles emitted in the RESS expansion are collected and incorporated into the coating on the substrate.
In three exemplary tests involving three (3) stents coated using the auxiliary emitter, coating efficiency values were: 45.6%, 39.6%, and 38.4%, respectively. Two tests without use of the auxiliary emitter gave coating efficiency values of 7.1% and 8.4%, respectively. Results demonstrate that certain embodiments enhance the charge and the collection (deposition) efficiency of the coating particles as compared to similar processes without the auxiliary emitter (i.e., charged ions). In particular, coating efficiencies with the auxiliary emitter are on the order of −45% presently, representing a 5-fold enhancement over conventional RESS coatings performed under otherwise comparable conditions without the auxiliary emitter. Results further show that e-RESS coatings can be effectively sintered (e.g., using heat sintering and/or gas/solvent sintering) to form dense, thermally stable single and multilayer films.
Particles that form coatings on a substrate can achieve a maximum density defined by particle close packing theory. For spherical particles of uniform size, this theoretical maximum is about 60 volume %. e-RESS coating particles prepared from various materials described herein (e.g., polymers and drugs) can be applied as single layers or as multiple layers at selected coating densities, e.g., on medical devices. Coatings applied in conjunction with some embodiments can be selected at coating densities of from about 1 volume % to about 60 volume %. Factors that define coating densities for selected applications include, but are not limited to, e.g., time of deposition, rate of deposition, solute concentrations, solvent ratios, number of coating layers, and combinations of these factors. In various embodiments, coatings composed of biosorbable polymers have been shown to produce coatings with selectable coating densities. In one exemplary test, a coating that included poly(lactic-co-glycolic acid, or PLGA) polymer at a solute concentration of 1 mg/mL was used to generate a coating density greater than about 5 volume % on a stent device, but density is not limited thereto. These coated polymers have also been shown to effectively release these drugs at the various coating densities selected. Coatings applied in some embodiments show an improvement in weight gain, an enhanced coating density, and a low dendricity.
Dendricity (or dendricity rating) is a qualitative measure that assesses the quality of a particular coating deposited in some embodiments on a scale of 1 (low dendricity) to 10 (high dendricity). A high dendricity rating is given to coatings that have a fuzzy or shaggy appearance under magnification, include a large quantity of fibers or particle accumulations on the surface, and have a poor coating density (<1 volume %). A low dendricity rating is given to coatings that are uniform, smooth, and have a high coating density (>1 volume %). Low dendricity e-RESS coatings produce more uniform and dense layers, which are advantageous for selected applications, including, e.g., coating of medical devices for use in biomedical applications.
While an exemplary embodiment has been shown and described, it will be apparent to those skilled in the art that many changes and modifications may be made without departing from the invention in its true scope and broader aspects. The appended claims are therefore intended to cover all such changes and modifications as fall within the spirit and scope of the invention.
The following examples will promote a further understanding of the invention and various aspects thereof.
Coating efficiency tests were conducted in a deposition vessel (e.g., 8-liter glass bell jar) centered over a base platform equipped with an auxiliary emitter and e-RESS expansion nozzle assembly. The invention auxiliary emitter was positioned at the top of, and external to, the deposition vessel. The auxiliary emitter was configured with a 1st auxiliary electrode consisting of a central stainless steel rod (⅛-inch diameter) having a tapered tip that was grounded, and a ring collector (⅛-inch copper) as a 2nd auxiliary electrode. Charged ions from the auxiliary emitter were carried in (e.g., N2) carrier gas into the deposition vessel. An exemplary flow rate of pure carrier gas (e.g., N2) through the auxiliary emitter was 4.5 L/min. The auxiliary emitter was operated at an exemplary current of 1 μA under current/feedback control. The e-RESS expansion nozzle assembly included a metal sheath, as a first e-RESS electrode composed of a length (˜4 inches) of stainless steel tubing (¼-inch O.D.) that surrounded an equal length of tubing ( 1/16-inch O.D.×0.0025-inch I.D.) composed of poly-ethyl-ethyl-ketone (PEEK) (IDEX, Northbrook, Ill., USA). The first e-RESS electrode was grounded. Three (3) stents, acting collectively as a 2nd e-RESS electrode, were mounted on twisted wire stent holders at positions 1, 4, and 9 of a 12-position, non-rotating stage equidistant from the e-RESS expansion nozzle. Wire stent holders were capped at the terminal ends with plastic beads to prevent coronal discharge. A voltage of −15 kV was applied to the stents. The vessel was purged with dry (N2) gas for >20 minutes to give a relative humidity below about 0.1%. A 50:50 Poly(DL-lactide-co-glycolide) bioabsorbable polymer (Catalog No. B6010-2P) available commercially (LACTEL® Absorbable Polymers, a division of Durectel, Corp., Pelham, Ala., U.S.A.) was prepared in a fluorohydrocarbon solvent (e.g., R-236ea [M.W. 152.04 g/moL], Dyneon, Oaksdale, Minn., USA) at a concentration of 1 mg/mL. The solvent solution was delivered through the expansion nozzle at a pressure of 5500 psi and an initial temperature of 150° C. Polymer expansion solution prepared in fluoropropane solvent (i.e., R-236ea) was sprayed at a pump flow rate of 7.5 mL/min for a time of ˜90 seconds. Flow rate of R-236ea gas [Pump flow rate (ml/min)×p(g/ml)×(1/MW (g/mol))×STP (L/mol)=L/min] was 1.7 L/min. Percentage of fluoropropane gas (R-236ea, Dyneon, Oakdale, Minn., USA) and N2 gas in the enclosure vessel was: 27% [(1.7/(1.7+4.5))×100=27%] and 73%, respectively. Moles of each gas in the enclosure vessel were 0.096 moles (R-236ea) and 0.26 moles (N2), respectively. Mole fractions for each gas in the enclosure vessel were 0.27 (R-236ea) and 0.73 (N2), respectively. Viscosity (at STP) of the gas mixture (R-236ea and N2) in the enclosure vessel at the end of the experiment was calculated from the Chapman-Enskog relation to be (minus) −14.5 μPa·sec.
Weight gains on each of the three stents from deposited coatings were: 380 μg, 430 μg, and 450 μg, respectively. In a second test, polymer expansion solution was sprayed for a time of ˜60 seconds at a flow rate of 7.4 mL/min. Charged ions from the auxiliary emitter were carried into the deposition vessel using (N2) gas at a flow rate of 6.5 L/min. Weight gains for each of the three stents from deposited coatings were: 232 μg, 252 μg, and 262 μg, respectively. In tests 1 and 2, moderate-to-heavy coatings were deposited to the stents. Test results showed the first stent had a lower coating weight that was attributed to: location on the mounting stage relative to the expansion nozzle, and lack of rotation of both the stent and stage. Dendricity values of from 1 to 2 were typical, as assessed by the minimal quantity of dendrite fibers observed (e.g., 50× magnification) on the surface. Collection efficiencies for these tests were 45.4% and 40.3%, respectively.
A test was performed as in Example 1 without use of the auxiliary emitter. Weight gains from deposited coatings for each of three stents were: 22 μg, 40 μg, and 42 μg, respectively. Coating efficiency for the test was 5.0%. Results showed coatings on the stents were light, non-uniform, and dendritic. Coatings were heaviest at the upper end of the stents and had a dendricity rating of ˜7, on average. Heavier coatings were observed near the top of the stents. Lighter coatings were observed at the mid-to-lower end of the stents, with some amount of the metal stent clearly visible through the coatings.
A dramatic effect is observed in weight gains for applied coatings at the initial onset of auxiliary emitter current. A gradual increase in weight gains occurs with increasing current between about 0.1 μA and 1 μA. Thereafter, a gradual decrease in weight gains occurs with change in auxiliary emitter current between about 1 μA and 5 μA, most likely due to a saturation of charge transferred to particles by the auxiliary emitter.
Use of an auxiliary emitter has demonstrated improvement in quality (e.g., dendricity, density, and weight) of electrostatically collected (deposited) coating particles on substrate surfaces. The auxiliary emitter has particular application to e-RESS coating processes, which coatings previous to the invention have been susceptible to formation of dendritic features.
This application is a division of U.S. application Ser. No. 12/748,134, filed on Mar. 26, 2010, which is incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3087860 | Endicott | Apr 1963 | A |
| 3123077 | Alcamo | Mar 1964 | A |
| 3457280 | Schmitt et al. | Jul 1969 | A |
| 3597449 | Deprospero et al. | Aug 1971 | A |
| 3929992 | Sehgal et al. | Dec 1975 | A |
| 4000137 | Dvonch et al. | Dec 1976 | A |
| 4285987 | Ayer et al. | Aug 1981 | A |
| 4289278 | Itoh | Sep 1981 | A |
| 4326532 | Hammar | Apr 1982 | A |
| 4336381 | Nagata et al. | Jun 1982 | A |
| 4582731 | Smith | Apr 1986 | A |
| 4655771 | Wallsten | Apr 1987 | A |
| 4733665 | Palmaz | Mar 1988 | A |
| 4734227 | Smith | Mar 1988 | A |
| 4734451 | Smith | Mar 1988 | A |
| 4931037 | Wetterman | Jun 1990 | A |
| 4950239 | Gahara | Aug 1990 | A |
| 4985625 | Hurst | Jan 1991 | A |
| 5000519 | Moore | Mar 1991 | A |
| 5071429 | Pinchuk et al. | Dec 1991 | A |
| 5090419 | Palestrant | Feb 1992 | A |
| 5096848 | Kawamura | Mar 1992 | A |
| 5106650 | Hoy et al. | Apr 1992 | A |
| 5158986 | Cha et al. | Oct 1992 | A |
| 5195969 | Wang et al. | Mar 1993 | A |
| 5243023 | Dezern | Sep 1993 | A |
| 5270086 | Hamlin | Dec 1993 | A |
| 5288711 | Mitchell et al. | Feb 1994 | A |
| 5324049 | Mistrater et al. | Jun 1994 | A |
| 5340614 | Perman et al. | Aug 1994 | A |
| 5342621 | Eury | Aug 1994 | A |
| 5350361 | Tsukashima et al. | Sep 1994 | A |
| 5350627 | Nemphos et al. | Sep 1994 | A |
| 5356433 | Rowland et al. | Oct 1994 | A |
| 5366504 | Andersen et al. | Nov 1994 | A |
| 5368045 | Clement et al. | Nov 1994 | A |
| 5372676 | Lowe | Dec 1994 | A |
| 5385776 | Maxfield et al. | Jan 1995 | A |
| 5403347 | Roby et al. | Apr 1995 | A |
| 5470603 | Staniforth et al. | Nov 1995 | A |
| 5494620 | Liu et al. | Feb 1996 | A |
| 5500180 | Anderson et al. | Mar 1996 | A |
| 5556383 | Wang et al. | Sep 1996 | A |
| 5562922 | Lambert | Oct 1996 | A |
| 5569463 | Helmus et al. | Oct 1996 | A |
| 5599576 | Opolski | Feb 1997 | A |
| 5609629 | Fearnot et al. | Mar 1997 | A |
| 5626611 | Liu et al. | May 1997 | A |
| 5626862 | Brem et al. | May 1997 | A |
| 5674242 | Phan et al. | Oct 1997 | A |
| 5725570 | Heath | Mar 1998 | A |
| 5800511 | Mayer | Sep 1998 | A |
| 5811032 | Kawai et al. | Sep 1998 | A |
| 5824049 | Ragheb et al. | Oct 1998 | A |
| 5837313 | Ding et al. | Nov 1998 | A |
| 5873904 | Ragheb et al. | Feb 1999 | A |
| 5876426 | Kume et al. | Mar 1999 | A |
| 5924631 | Rodrigues et al. | Jul 1999 | A |
| 5948020 | Yoon et al. | Sep 1999 | A |
| 5957975 | Lafont et al. | Sep 1999 | A |
| 5980972 | Ding | Nov 1999 | A |
| 6013855 | McPherson et al. | Jan 2000 | A |
| 6077880 | Castillo et al. | Jun 2000 | A |
| 6129755 | Mathis et al. | Oct 2000 | A |
| 6143037 | Goldsten et al. | Nov 2000 | A |
| 6143314 | Chandrashekar et al. | Nov 2000 | A |
| 6146356 | Wang et al. | Nov 2000 | A |
| 6146404 | Kim et al. | Nov 2000 | A |
| 6153252 | Hossainy et al. | Nov 2000 | A |
| 6171327 | Daniel et al. | Jan 2001 | B1 |
| 6190699 | Luzzi et al. | Feb 2001 | B1 |
| 6206914 | Soykan et al. | Mar 2001 | B1 |
| 6231600 | Zhong et al. | May 2001 | B1 |
| 6245104 | Alt | Jun 2001 | B1 |
| 6248127 | Shah et al. | Jun 2001 | B1 |
| 6248129 | Froix | Jun 2001 | B1 |
| 6273913 | Wright et al. | Aug 2001 | B1 |
| 6280802 | Akedo | Aug 2001 | B1 |
| 6284758 | Egi et al. | Sep 2001 | B1 |
| 6309669 | Setterstrom et al. | Oct 2001 | B1 |
| 6319541 | Pletcher et al. | Nov 2001 | B1 |
| 6336934 | Gilson et al. | Jan 2002 | B1 |
| 6342062 | Suon et al. | Jan 2002 | B1 |
| 6355691 | Goodman | Mar 2002 | B1 |
| 6358556 | Ding et al. | Mar 2002 | B1 |
| 6361819 | Tedeschi et al. | Mar 2002 | B1 |
| 6364903 | Tseng et al. | Apr 2002 | B2 |
| 6368658 | Schwarz et al. | Apr 2002 | B1 |
| 6372246 | Wei et al. | Apr 2002 | B1 |
| 6387121 | Alt | May 2002 | B1 |
| 6409716 | Sahatjian et al. | Jun 2002 | B1 |
| 6414050 | Howdle et al. | Jul 2002 | B1 |
| 6416779 | D'Augustine et al. | Jul 2002 | B1 |
| 6448315 | Lidgren et al. | Sep 2002 | B1 |
| 6461644 | Jackson et al. | Oct 2002 | B1 |
| 6495163 | Jordan | Dec 2002 | B1 |
| 6497729 | Moussy et al. | Dec 2002 | B1 |
| 6506213 | Mandel et al. | Jan 2003 | B1 |
| 6517860 | Rosser et al. | Feb 2003 | B1 |
| 6521258 | Mandel et al. | Feb 2003 | B1 |
| 6524698 | Schmoock | Feb 2003 | B1 |
| 6537310 | Palmaz et al. | Mar 2003 | B1 |
| 6541033 | Shah | Apr 2003 | B1 |
| 6572813 | Zhang et al. | Jun 2003 | B1 |
| 6610013 | Fenster et al. | Aug 2003 | B1 |
| 6627246 | Mehta et al. | Sep 2003 | B2 |
| 6649627 | Cecchi et al. | Nov 2003 | B1 |
| 6660176 | Tepper et al. | Dec 2003 | B2 |
| 6669785 | DeYoung et al. | Dec 2003 | B2 |
| 6669980 | Hanson et al. | Dec 2003 | B2 |
| 6670407 | Howdle et al. | Dec 2003 | B2 |
| 6682757 | Wright | Jan 2004 | B1 |
| 6706283 | Appel et al. | Mar 2004 | B1 |
| 6710059 | Labrie et al. | Mar 2004 | B1 |
| 6720003 | Cheng et al. | Apr 2004 | B2 |
| 6726712 | Raeder-Devens et al. | Apr 2004 | B1 |
| 6736996 | Carbonell et al. | May 2004 | B1 |
| 6743505 | Antal et al. | Jun 2004 | B2 |
| 6749902 | Yonker et al. | Jun 2004 | B2 |
| 6755871 | Damaso et al. | Jun 2004 | B2 |
| 6756084 | Fulton et al. | Jun 2004 | B2 |
| 6767558 | Wang et al. | Jul 2004 | B2 |
| 6780475 | Fulton et al. | Aug 2004 | B2 |
| 6794902 | Becker et al. | Sep 2004 | B2 |
| 6800663 | Asgarzadeh et al. | Oct 2004 | B2 |
| 6815218 | Jacobsen et al. | Nov 2004 | B1 |
| 6821549 | Jayaraman | Nov 2004 | B2 |
| 6837611 | Kuo et al. | Jan 2005 | B2 |
| 6838089 | Carlsson et al. | Jan 2005 | B1 |
| 6838528 | Zhao | Jan 2005 | B2 |
| 6858598 | McKearn et al. | Feb 2005 | B1 |
| 6860123 | Uhlin et al. | Mar 2005 | B1 |
| 6884377 | Burnham et al. | Apr 2005 | B1 |
| 6884823 | Plerick et al. | Apr 2005 | B1 |
| 6897205 | Beckert et al. | May 2005 | B2 |
| 6905555 | DeYoung et al. | Jun 2005 | B2 |
| 6908624 | Hossainy et al. | Jun 2005 | B2 |
| 6916800 | McKearn et al. | Jul 2005 | B2 |
| 6923979 | Fotland et al. | Aug 2005 | B2 |
| 6939569 | Green et al. | Sep 2005 | B1 |
| 6973718 | Sheppard et al. | Dec 2005 | B2 |
| 7148201 | Stern et al. | Dec 2006 | B2 |
| 7152452 | Kokish | Dec 2006 | B2 |
| 7160592 | Rypacek et al. | Jan 2007 | B2 |
| 7163715 | Kramer | Jan 2007 | B1 |
| 7169404 | Hossainy et al. | Jan 2007 | B2 |
| 7171255 | Holupka et al. | Jan 2007 | B2 |
| 7201750 | Eggers et al. | Apr 2007 | B1 |
| 7201940 | Kramer | Apr 2007 | B1 |
| 7229837 | Chen | Jun 2007 | B2 |
| 7279174 | Pacetti et al. | Oct 2007 | B2 |
| 7282020 | Kaplan | Oct 2007 | B2 |
| 7308748 | Kokish | Dec 2007 | B2 |
| 7326734 | Zi et al. | Feb 2008 | B2 |
| 7378105 | Burke et al. | May 2008 | B2 |
| 7419696 | Berg et al. | Sep 2008 | B2 |
| 7429378 | Serhan et al. | Sep 2008 | B2 |
| 7444162 | Hassan | Oct 2008 | B2 |
| 7455688 | Furst et al. | Nov 2008 | B2 |
| 7456151 | Li et al. | Nov 2008 | B2 |
| 7462593 | Cuttitta et al. | Dec 2008 | B2 |
| 7485113 | Varner et al. | Feb 2009 | B2 |
| 7488389 | Osawa | Feb 2009 | B2 |
| 7524865 | D'Amato et al. | Apr 2009 | B2 |
| 7537610 | Reiss | May 2009 | B2 |
| 7537785 | Loscalzo et al. | May 2009 | B2 |
| 7553827 | Attawia et al. | Jun 2009 | B2 |
| 7713538 | Lewis et al. | May 2010 | B2 |
| 7727275 | Betts et al. | Jun 2010 | B2 |
| 7763277 | Canham et al. | Jul 2010 | B1 |
| 7837726 | Von Oepen et al. | Nov 2010 | B2 |
| 7919108 | Rees et al. | Apr 2011 | B2 |
| 7955383 | Krivoruchko et al. | Jun 2011 | B2 |
| 7972661 | Pui et al. | Jul 2011 | B2 |
| 8298565 | Taylor et al. | Oct 2012 | B2 |
| 8758429 | Taylor et al. | Jun 2014 | B2 |
| 8795762 | Fulton et al. | Aug 2014 | B2 |
| 8834913 | Shaw et al. | Sep 2014 | B2 |
| 20010026804 | Boutignon | Oct 2001 | A1 |
| 20010034336 | Shah et al. | Oct 2001 | A1 |
| 20010044629 | Stinson | Nov 2001 | A1 |
| 20010049551 | Tseng et al. | Dec 2001 | A1 |
| 20020007209 | Scheerder et al. | Jan 2002 | A1 |
| 20020051845 | Mehta et al. | May 2002 | A1 |
| 20020082680 | Shanley et al. | Jun 2002 | A1 |
| 20020091433 | Ding et al. | Jul 2002 | A1 |
| 20020099332 | Slepian et al. | Jul 2002 | A1 |
| 20020125860 | Schworm et al. | Sep 2002 | A1 |
| 20020133072 | Wang et al. | Sep 2002 | A1 |
| 20020144757 | Craig et al. | Oct 2002 | A1 |
| 20030001830 | Wampler et al. | Jan 2003 | A1 |
| 20030031699 | Van Antwerp | Feb 2003 | A1 |
| 20030077200 | Craig et al. | Apr 2003 | A1 |
| 20030088307 | Shulze et al. | May 2003 | A1 |
| 20030125800 | Shulze et al. | Jul 2003 | A1 |
| 20030143315 | Pui et al. | Jul 2003 | A1 |
| 20030170305 | O'Neil et al. | Sep 2003 | A1 |
| 20030180376 | Dalal et al. | Sep 2003 | A1 |
| 20030185964 | Weber et al. | Oct 2003 | A1 |
| 20030204238 | Tedeschi | Oct 2003 | A1 |
| 20030222017 | Fulton et al. | Dec 2003 | A1 |
| 20030222018 | Yonker et al. | Dec 2003 | A1 |
| 20030222019 | Fulton et al. | Dec 2003 | A1 |
| 20030232014 | Burke et al. | Dec 2003 | A1 |
| 20040013792 | Epstein et al. | Jan 2004 | A1 |
| 20040018228 | Fischell et al. | Jan 2004 | A1 |
| 20040022853 | Ashton et al. | Feb 2004 | A1 |
| 20040044397 | Stinson | Mar 2004 | A1 |
| 20040059290 | Palasis | Mar 2004 | A1 |
| 20040106982 | Jalisi | Jun 2004 | A1 |
| 20040122205 | Nathan | Jun 2004 | A1 |
| 20040126542 | Fujiwara et al. | Jul 2004 | A1 |
| 20040143317 | Stinson et al. | Jul 2004 | A1 |
| 20040157789 | Geall | Aug 2004 | A1 |
| 20040170685 | Carpenter et al. | Sep 2004 | A1 |
| 20040193177 | Houghton et al. | Sep 2004 | A1 |
| 20040193262 | Shadduck | Sep 2004 | A1 |
| 20040220660 | Shanley et al. | Nov 2004 | A1 |
| 20040224001 | Pacetti et al. | Nov 2004 | A1 |
| 20040236416 | Falotico | Nov 2004 | A1 |
| 20040260000 | Chaiko | Dec 2004 | A1 |
| 20050003074 | Brown et al. | Jan 2005 | A1 |
| 20050004661 | Lewis et al. | Jan 2005 | A1 |
| 20050010275 | Sahatjian et al. | Jan 2005 | A1 |
| 20050015046 | Weber et al. | Jan 2005 | A1 |
| 20050019747 | Anderson et al. | Jan 2005 | A1 |
| 20050038498 | Dubrow et al. | Feb 2005 | A1 |
| 20050048121 | East et al. | Mar 2005 | A1 |
| 20050049694 | Neary | Mar 2005 | A1 |
| 20050069630 | Fox et al. | Mar 2005 | A1 |
| 20050070990 | Stinson | Mar 2005 | A1 |
| 20050075714 | Cheng et al. | Apr 2005 | A1 |
| 20050079199 | Heruth et al. | Apr 2005 | A1 |
| 20050079274 | Palasis et al. | Apr 2005 | A1 |
| 20050084533 | Howdle et al. | Apr 2005 | A1 |
| 20050131513 | Myers | Jun 2005 | A1 |
| 20050147734 | Seppala et al. | Jul 2005 | A1 |
| 20050166841 | Robida | Aug 2005 | A1 |
| 20050175772 | Worsham et al. | Aug 2005 | A1 |
| 20050177223 | Palmaz | Aug 2005 | A1 |
| 20050191491 | Wang et al. | Sep 2005 | A1 |
| 20050196424 | Chappa | Sep 2005 | A1 |
| 20050208102 | Schultz | Sep 2005 | A1 |
| 20050216075 | Wang et al. | Sep 2005 | A1 |
| 20050238829 | Motherwell et al. | Oct 2005 | A1 |
| 20050255327 | Chaney et al. | Nov 2005 | A1 |
| 20050260186 | Bookbinder et al. | Nov 2005 | A1 |
| 20050268573 | Yan | Dec 2005 | A1 |
| 20050288481 | DesNoyer et al. | Dec 2005 | A1 |
| 20060001011 | Wilson et al. | Jan 2006 | A1 |
| 20060020325 | Burgermeister et al. | Jan 2006 | A1 |
| 20060030652 | Adams et al. | Feb 2006 | A1 |
| 20060045901 | Weber | Mar 2006 | A1 |
| 20060089705 | Ding et al. | Apr 2006 | A1 |
| 20060093771 | Rypacek et al. | May 2006 | A1 |
| 20060094744 | Maryanoff et al. | May 2006 | A1 |
| 20060116755 | Stinson | Jun 2006 | A1 |
| 20060121080 | Lye et al. | Jun 2006 | A1 |
| 20060121089 | Michal et al. | Jun 2006 | A1 |
| 20060134211 | Lien et al. | Jun 2006 | A1 |
| 20060136041 | Schmid et al. | Jun 2006 | A1 |
| 20060147698 | Carroll et al. | Jul 2006 | A1 |
| 20060153729 | Stinson et al. | Jul 2006 | A1 |
| 20060160455 | Sugyo et al. | Jul 2006 | A1 |
| 20060188547 | S. Bezwada | Aug 2006 | A1 |
| 20060193886 | Owens et al. | Aug 2006 | A1 |
| 20060193887 | Owens et al. | Aug 2006 | A1 |
| 20060193890 | Owens et al. | Aug 2006 | A1 |
| 20060198868 | DeWitt et al. | Sep 2006 | A1 |
| 20060210638 | Liversidge et al. | Sep 2006 | A1 |
| 20060210639 | Liversidge et al. | Sep 2006 | A1 |
| 20060216324 | Stucke et al. | Sep 2006 | A1 |
| 20060222756 | Davila et al. | Oct 2006 | A1 |
| 20060228415 | Oberegger et al. | Oct 2006 | A1 |
| 20060276877 | Owens et al. | Dec 2006 | A1 |
| 20060276885 | Owens et al. | Dec 2006 | A1 |
| 20070009564 | McClain et al. | Jan 2007 | A1 |
| 20070032864 | Furst et al. | Feb 2007 | A1 |
| 20070038227 | Massicotte et al. | Feb 2007 | A1 |
| 20070059350 | Kennedy et al. | Mar 2007 | A1 |
| 20070110888 | Radhakrishnan et al. | May 2007 | A1 |
| 20070123973 | Roth et al. | May 2007 | A1 |
| 20070123977 | Cottone et al. | May 2007 | A1 |
| 20070128274 | Zhu et al. | Jun 2007 | A1 |
| 20070148251 | Hossainy et al. | Jun 2007 | A1 |
| 20070154554 | Burgermeister et al. | Jul 2007 | A1 |
| 20070196423 | Ruane et al. | Aug 2007 | A1 |
| 20070198081 | Castro et al. | Aug 2007 | A1 |
| 20070203569 | Burgermeister et al. | Aug 2007 | A1 |
| 20070259017 | Francis | Nov 2007 | A1 |
| 20070280992 | Margaron et al. | Dec 2007 | A1 |
| 20080051866 | Chen et al. | Feb 2008 | A1 |
| 20080071359 | Thornton et al. | Mar 2008 | A1 |
| 20080075753 | Chappa | Mar 2008 | A1 |
| 20080077232 | Nishide | Mar 2008 | A1 |
| 20080095919 | McClain et al. | Apr 2008 | A1 |
| 20080097575 | Cottone | Apr 2008 | A1 |
| 20080097591 | Savage et al. | Apr 2008 | A1 |
| 20080107702 | Jennissen | May 2008 | A1 |
| 20080118543 | Pacetti et al. | May 2008 | A1 |
| 20080124372 | Hossainy et al. | May 2008 | A1 |
| 20080138375 | Yan et al. | Jun 2008 | A1 |
| 20080206304 | Lindquist et al. | Aug 2008 | A1 |
| 20080213464 | O'Connor | Sep 2008 | A1 |
| 20080255508 | Wang | Oct 2008 | A1 |
| 20080255510 | Wang | Oct 2008 | A1 |
| 20080269449 | Chattopadhyay et al. | Oct 2008 | A1 |
| 20080292776 | Dias et al. | Nov 2008 | A1 |
| 20080003006 | McKinnon et al. | Dec 2008 | A1 |
| 20080300669 | Hossainy | Dec 2008 | A1 |
| 20090027947 | Takeda | Jan 2009 | A1 |
| 20090043379 | Prescott | Feb 2009 | A1 |
| 20090062909 | Taylor et al. | Mar 2009 | A1 |
| 20090068266 | Raheja et al. | Mar 2009 | A1 |
| 20090076446 | Dubuclet, IV et al. | Mar 2009 | A1 |
| 20090082855 | Borges et al. | Mar 2009 | A1 |
| 20090098178 | Hofmann et al. | Apr 2009 | A1 |
| 20090105809 | Lee et al. | Apr 2009 | A1 |
| 20090110711 | Trollsas et al. | Apr 2009 | A1 |
| 20090111787 | Lim et al. | Apr 2009 | A1 |
| 20090123515 | Taylor et al. | May 2009 | A1 |
| 20090186069 | DeYoung et al. | Jul 2009 | A1 |
| 20090202609 | Keough et al. | Aug 2009 | A1 |
| 20090216317 | Cromack et al. | Aug 2009 | A1 |
| 20090227949 | Knapp et al. | Sep 2009 | A1 |
| 20090231578 | Ling et al. | Sep 2009 | A1 |
| 20090263460 | McDonald | Oct 2009 | A1 |
| 20090002927 | Nesbitt et al. | Nov 2009 | A1 |
| 20090285974 | Kerrigan et al. | Nov 2009 | A1 |
| 20090292351 | McClain et al. | Nov 2009 | A1 |
| 20090292776 | Nesbitt et al. | Nov 2009 | A1 |
| 20090003006 | Conte et al. | Dec 2009 | A1 |
| 20090297578 | Trollsas et al. | Dec 2009 | A1 |
| 20090300689 | Conte et al. | Dec 2009 | A1 |
| 20100015200 | McClain et al. | Jan 2010 | A1 |
| 20100030261 | McClain | Feb 2010 | A1 |
| 20100042206 | Yadav et al. | Feb 2010 | A1 |
| 20100055145 | Betts et al. | Mar 2010 | A1 |
| 20100055294 | Wang et al. | Mar 2010 | A1 |
| 20100063570 | Pacetti et al. | Mar 2010 | A1 |
| 20100063580 | McClain et al. | Mar 2010 | A1 |
| 20100074934 | Hunter | Mar 2010 | A1 |
| 20100155496 | Stark et al. | Jun 2010 | A1 |
| 20100166869 | Desai et al. | Jul 2010 | A1 |
| 20100196482 | Radovic-Moreno et al. | Aug 2010 | A1 |
| 20100198330 | Hossainy et al. | Aug 2010 | A1 |
| 20100198331 | Rapoza et al. | Aug 2010 | A1 |
| 20100198343 | Hossainy et al. | Aug 2010 | A1 |
| 20100211164 | McClain et al. | Aug 2010 | A1 |
| 20100228348 | McClain et al. | Sep 2010 | A1 |
| 20100233332 | Xing et al. | Sep 2010 | A1 |
| 20100239635 | McClain et al. | Sep 2010 | A1 |
| 20100241220 | McClain et al. | Sep 2010 | A1 |
| 20100256746 | Taylor et al. | Oct 2010 | A1 |
| 20100256748 | Taylor et al. | Oct 2010 | A1 |
| 20100272778 | McClain et al. | Oct 2010 | A1 |
| 20100298928 | McClain et al. | Nov 2010 | A1 |
| 20110009953 | Luk et al. | Jan 2011 | A1 |
| 20110034422 | Kannan et al. | Feb 2011 | A1 |
| 20110159069 | Shaw et al. | Jun 2011 | A1 |
| 20110160751 | Granja Filho | Jun 2011 | A1 |
| 20110190864 | McClain et al. | Aug 2011 | A1 |
| 20110238161 | Fulton et al. | Sep 2011 | A1 |
| 20110257732 | McClain et al. | Oct 2011 | A1 |
| 20110264190 | McClain et al. | Oct 2011 | A1 |
| 20110301697 | Hoffmann et al. | Dec 2011 | A1 |
| 20120064124 | McClain et al. | Mar 2012 | A1 |
| 20120064143 | Sharp et al. | Mar 2012 | A1 |
| 20120065723 | Drasler et al. | Mar 2012 | A1 |
| 20120101566 | Mews et al. | Apr 2012 | A1 |
| 20120150275 | Shaw-Klein | Jun 2012 | A1 |
| 20120172787 | McClain et al. | Jul 2012 | A1 |
| 20120177742 | McClain et al. | Jul 2012 | A1 |
| 20120271396 | Zheng et al. | Oct 2012 | A1 |
| 20120280432 | Chen et al. | Nov 2012 | A1 |
| 20120323311 | McClain et al. | Dec 2012 | A1 |
| 20130006351 | Taylor et al. | Jan 2013 | A1 |
| 20130172853 | McClain et al. | Jul 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| 2589761 | Dec 2004 | CA |
| 1465410 | Jan 2004 | CN |
| 1649551 | Aug 2005 | CN |
| 0604022 | Jun 1994 | EP |
| 0982041 | Mar 2000 | EP |
| 1195822 | Apr 2002 | EP |
| 1454677 | Sep 2004 | EP |
| 2197070 | Jun 2010 | EP |
| 2293357 | Mar 2011 | EP |
| 2293366 | Mar 2011 | EP |
| 1994-098902 | Apr 1994 | JP |
| H09-056807 | Mar 1997 | JP |
| 2003-205037 | Jul 2003 | JP |
| 2003-533286 | Nov 2003 | JP |
| 2003-5339493 | Nov 2003 | JP |
| 2003533492 | Nov 2003 | JP |
| 2004-158458 | Jun 2004 | JP |
| 2004173770 | Jun 2004 | JP |
| 2004-529674 | Sep 2004 | JP |
| 2005-505318 | Feb 2005 | JP |
| 2005-523119 | Aug 2005 | JP |
| 2005-523332 | Aug 2005 | JP |
| 2005-296690 | Oct 2005 | JP |
| 2009-501566 | Jan 2009 | JP |
| 10-2004-0034064 | Apr 2004 | KR |
| WO-9506487 | Mar 1995 | WO |
| WO-9620698 | Jul 1996 | WO |
| WO-9745502 | Dec 1997 | WO |
| WO-0154662 | Aug 2001 | WO |
| WO-01-87371 | Nov 2001 | WO |
| WO-0187372 | Nov 2001 | WO |
| WO-0240702 | May 2002 | WO |
| WO-0243799 | Jun 2002 | WO |
| WO-02-074194 | Sep 2002 | WO |
| WO-02090085 | Nov 2002 | WO |
| WO-03039553 | May 2003 | WO |
| WO-03-082368 | Oct 2003 | WO |
| WO-03101624 | Dec 2003 | WO |
| WO-2004009145 | Jan 2004 | WO |
| WO-2004028589 | Apr 2004 | WO |
| WO-2004043506 | May 2004 | WO |
| WO-2004045450 | Jun 2004 | WO |
| WO-2004098574 | Nov 2004 | WO |
| WO-2005042623 | May 2005 | WO |
| WO-2005063319 | Jul 2005 | WO |
| WO-2005069889 | Aug 2005 | WO |
| WO-2005117942 | Dec 2005 | WO |
| WO-2006014534 | Feb 2006 | WO |
| WO-2006052575 | May 2006 | WO |
| WO-2006065685 | Jun 2006 | WO |
| WO-2006083796 | Aug 2006 | WO |
| WO-2006099276 | Sep 2006 | WO |
| WO-2007-002238 | Jan 2007 | WO |
| WO 2007011707 | Jan 2007 | WO |
| WO-2007011708 | Jan 2007 | WO |
| WO-2007092179 | Aug 2007 | WO |
| WO-2007127363 | Nov 2007 | WO |
| WO 2007143609 | Dec 2007 | WO |
| WO-2008042909 | Apr 2008 | WO |
| WO-2008046641 | Apr 2008 | WO |
| WO-2008046642 | Apr 2008 | WO |
| WO-2008052000 | May 2008 | WO |
| 2008070996 | Jun 2008 | WO |
| WO-2008070996 | Jun 2008 | WO |
| WO-2008086369 | Jul 2008 | WO |
| WO 2008131131 | Oct 2008 | WO |
| WO-2008148013 | Dec 2008 | WO |
| 2009051780 | Apr 2009 | WO |
| WO 2009051780 | Apr 2009 | WO |
| WO-20090146209 | Dec 2009 | WO |
| WO-2010009335 | Jan 2010 | WO |
| WO-2010075590 | Jul 2010 | WO |
| WO-2010111196 | Sep 2010 | WO |
| WO-2010111196 | Sep 2010 | WO |
| WO-2010111232 | Sep 2010 | WO |
| WO-2010111232 | Sep 2010 | WO |
| WO-2010111238 | Sep 2010 | WO |
| WO-2010111238 | Sep 2010 | WO |
| WO-2010111238 | Oct 2010 | WO |
| WO-2010120552 | Oct 2010 | WO |
| WO-2010121187 | Oct 2010 | WO |
| WO-2010121187 | Oct 2010 | WO |
| WO-2011009096 | Jan 2011 | WO |
| WO-2011097103 | Aug 2011 | WO |
| WO-2011119762 | Sep 2011 | WO |
| WO-2011130448 | Oct 2011 | WO |
| WO-2011133655 | Oct 2011 | WO |
| WO-2012009684 | Jan 2012 | WO |
| WO-2012034079 | Mar 2012 | WO |
| WO-2012082502 | Jun 2012 | WO |
| WO-2012092504 | Jul 2012 | WO |
| WO-2012142319 | Oct 2012 | WO |
| WO-2012166819 | Dec 2012 | WO |
| WO-2013012689 | Jan 2013 | WO |
| WO-2013025535 | Feb 2013 | WO |
| WO-2013059509 | Apr 2013 | WO |
| WO-2013173657 | Nov 2013 | WO |
| WO-2013177211 | Nov 2013 | WO |
| WO-2014063111 | Apr 2014 | WO |
| Entry |
|---|
| Abreu Filho et al., “Influence of metal alloy and the profile of coronary stents in patients with multi-vessel coronary disease.” Clinics 66(6):985-989 (2011). |
| Akoh et al., “One-Stage Synthesis of Raffinose Fatty Acid Polyesters.” Journal Food Science 52:1570 (1987). |
| Albert et al., “Antibiotics for preventing recurrent urinary tract infection in non-pregnant women.” Cochrane Database System Rev. 3, CD001209 (2004). |
| Au et al., “Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial.” Journal of the National Cancer Institute, 93(8), 597-604 (2001). |
| AU2006270221 Exam Report dated Apr. 6, 2010. |
| AU2007243268 Exam Report dated May 15, 2013. |
| AU2007243268 Exam Report dated Aug. 31, 2011. |
| AU2009251504 Exam Report dated Dec. 8, 2011. |
| AU2009270849 Exam Report dated Feb. 14, 2012. |
| AU2011232760 Exam Report dated Apr. 10, 2013. |
| AU2011256902 Exam Report dated Jun. 13, 2013. |
| AU2012203203 Exam Report dated Apr. 12, 2013. |
| AU2012203577 Exam Report dated Jun. 7, 2013. |
| AU2011256902 Office Action dated Jun. 10, 2014. |
| Balss et al., “Quantitative spatial distribution of sirolumus and polymers in drug-eluting stents using confocal Raman microscopy.” J. of Biomedical Materials Research Part A, 258-270 (2007). |
| Belu et al., “Three-Dimensional Compositional Analysis of Drug Eluting Stent Coatings Using Cluster Secondary Loan Mass Spectroscopy.” Anal. Chem. 80:624-632 (2008). |
| Belu, et al., “Chemical imaging of drug eluting coatings: Combining surface analysis and confocal Rama microscopy.” J. Controlled Release 126: 111-121 (2008). |
| Boneff, “Topical Treatment of Chronic Prostatitis and Premature Ejaculation,” International Urology and Nephrology 4(2):183-186 (1971). |
| Bookbinder et al., “A recombinant human enzyme for enhanced interstitial transport of therapeutics.” Journal of Controlled Release 114:230-241 (2006). |
| Borchert et al., “Prevention and treatement of urinary tract infection with probiotics: Review and research perspective,” Indian Journal Urol. 24(2):139-144 (2008). |
| Brunstein et al., “Histamine, a vasoactive agent with vascular disrupting potential improves tumour response by enhancing local drug delivery,” British Journal of Cancer 95:1663-1669 (2006). |
| CA 2757276 Office Action dated Feb. 15, 2013. |
| CA 2757276 Office Action dated Feb. 5, 2014. |
| CA 2794704 Office Action dated Feb. 7, 2014. |
| CA 2613280 Office Action dated Oct. 2, 2012. |
| CA 2615452 Office Action dated Dec. 19, 2012. |
| CA 2615452 Office Action dated Oct. 8, 2013. |
| CA 2650590 Office Action dated Jul. 23, 2013. |
| CA 2613280 Office Action dated Dec. 10, 2013. |
| CA 2667228 Office Action dated Jan. 22, 2014. |
| CA 2679712 Office Action dated Feb. 24, 2014. |
| CA 2684482 Office Action dated Nov. 10, 2011. |
| CA 2684482 Office Action dated Jul. 11, 2012. |
| CA 2688314 Office Action dated Jun. 6, 2012. |
| CA 2667228 Office Action dated May 7, 2013. |
| CA 2730995 Office Action dated May 29, 2013. |
| CA 2730995 Office Action dated Sep. 26, 2012. |
| CA 2730995 Office Action dated Feb. 20, 2014. |
| CA 2756307 Office Action dated Feb. 18, 2013. |
| CA 2756307 Office Action dated Mar. 24,2014. |
| CA 2756386 Office Action dated Mar. 15, 2013. |
| CA 2756388 Office Action dated Apr. 11, 2013. |
| CA 2756388 Office Action dated Apr. 14, 2014. |
| CA 2759015 Office Action dated Apr. 8, 2013. |
| CA 2759015 Office Action dated Jul. 21, 2014. |
| CA 2756386 Office Action dated Oct. 24, 2013. |
| CA 2756386 Office Action dated May 16, 2014. |
| CA 2805631 Office Action dated Jan. 17, 2014. |
| CA 2823355 Office action dated Apr. 14, 2014. |
| Cadieux et al., “Use of triclosan-eluting ureteral stents in patients with long-term stents.” J. Endourol (Epub) (Jun. 19, 2009). |
| Channon et al., “Nitric Oxide Synthase in Atherosclerosis and Vascular Injury: Insights from Experimental Gene Therapy.” Arteriosclerosis, Thrombosis and Vascular Biology, 20(8):1873-1881 (2000). |
| Chen et al. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. Biomaterials. 26(35):7418-24 (2005). |
| Chopek et al. “The influence of carbon fibres on the resorption time and mechanical properties of the lactide-glycolide co-polymer.” J. Biomater. Sci. Polymer Edn, vol. 18, No. 11, pp. 1355-1368 (2007). |
| Clair and Burks, “Thermoplastic/Melt-Processable Polyimides,” NASA Conf. Pub. #2334, pp. 337-355 (1984). |
| CN 2006800258093 Office Action dated May 30, 2012. |
| CN 200780047425.6 Office Action dated Aug. 3, 2012. |
| CN 200780047425.6 Office Action dated Feb. 28, 2013. |
| CN 200880007308.1 Office Action dated Jul. 3, 2013. |
| CN 200880007308.1 Office Action dated Nov. 23, 2011. |
| CN 200880007308.1 Office Action dated Oct. 18, 2012. |
| CN 200880007308.1 Office Action dated Jan. 2, 2014. |
| CN 200880020515 Office Action dated Jul. 22, 2013. |
| CN 200880020515 Office Action dated Oct. 9, 2012. |
| CN 200880020515 Office Action dated Apr. 15, 2014. |
| CN 200880100102.3 Office Action dated Apr. 11, 2013. |
| CN 200880100102.3 Office Action dated Jun. 1, 2012. |
| CN 200880100102.3 Office Action dated Dec. 11, 2013. |
| CN 200880100102.3 Office Action dated Aug. 27, 2014. |
| CN 200980122691 Office Action dated Oct. 10, 2012. |
| CN 200980136432.2 Office Action dated Jan. 14, 2013. |
| CN 200980136432.2 Office Action dated Nov. 4, 2013. |
| CN 200980136432.2 Office Action dated Jul. 3, 2014. |
| CN 201080024973.9 Office Action dated Dec. 20, 2013. |
| CN 201080024973.9 Office Action dated Aug. 7, 2014. |
| Cohen, et al. “Sintering Technique for the Preparation of Polymer Matrices for the Controlled Release of Macromolecules.” Journal of Pharmaceutical Sciences, 73:8, 1034-1037 (1984). |
| Colombo et al. “Selection of Coronary Stents.” Journal of the American College of Cardiology, vol. 40, No. 6, p. 1021-1033 (2002). |
| CRC Handbook of chemistry and physics. 71st ed. David R. Lide, Editor-in-Chief. Boca Raton, FL, CRC Press; 1990; 6-140. |
| Cyrus et al., “Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury.” Arterioscler Thromb Vasc Biol 28:820-826 (2008). |
| Derwent-Acc-No. 2004-108578 Abstracting 2004003077; Jan. 8, 2004; 3 pages. |
| DiStasi et al., “Percutaneous sequential bacillus Calmette-Guerin and mitomycin C for panurothelial carcinomatosis,” Can. J. Urol. 12(6):2895-2898 (2005). |
| Domb and Langer, “Polyanhydrides. I. Preparation of High Molecular Weight Polyanhydrides.”J. Polym Sci. 25:3373-3386 (1987). |
| Domingo, C. et al., “Precipication of ultrafine organic crystals from the rapid expansion of supercritical solutions over a capillary and a frit nozzle.” J. Supercritical Fluids 10:39-55 (1997). |
| Dzik-Jurasz, “Molecular imaging in vivo: an introduction.” The British Journal of Radiology, 76:S98-S109 (2003). |
| EA 200901254 Office Action dated Jul. 29, 2013. |
| EA 200901254/28 Office Action dated Jun. 28, 2012. |
| EA 201001497 Office Action dated Feb. 13, 2013. |
| EA 201001497 Office Action dated Jul. 29, 2013. |
| Electrostatic Process, Wiley Encyclopedia of Electrical and Electronics Engineering, John Wiley & Sons, Inc. 1999; 7:15-39. |
| Eltze et al., “Imidazoquinolinon, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly (ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors,” Mol. Pharmacol 74(6):1587-1598 (2008). |
| EP06773731.2 Search Report dated Oct. 2, 2012. |
| EP06787258.0 Office Action dated Mar. 15, 2013. |
| EP06787258.0 Search Report dated Feb. 6, 2012. |
| EP07756094.4 Office Action dated Jan. 21, 2014. |
| EP07756094.4 Office Action dated May 29, 2013. |
| EP07756094.4 Search Report dated Aug. 31, 2012. |
| EP08705772.5 Office Action dated Oct. 30, 2013. |
| EP08705772.5 Search Report dated Feb. 20, 2013. |
| EP08733210.2 Office Action dated Jul. 16, 2013. |
| EP08733210.2 Search Report dated Oct. 23, 2012. |
| EP08756215.3 Search Report dated Oct. 5, 2011. |
| EP08756215.3 Search Report dated Jan. 28, 2013. |
| EP09755571.8 Office Action dated Dec. 13, 2013. |
| EP09755571.8 Search Report dated Apr. 9, 2013. |
| EP09798764.8 Search Report dated Sep. 30, 2013. |
| EP09805981.9 Office Action dated Feb. 13, 2013. |
| EP10756676.2 Search Report dated Jan. 31, 2014. |
| EP10756696.0 Search Report dated Oct. 10, 2013. |
| EP10764884.2 Search Report dated Oct. 28, 2013. |
| EP10765295.0 Search Report dated Oct. 17, 2013. |
| EP11769546.0 Search Report dated Sep. 19, 2013. |
| EP10800642.0 Search Report dated Mar. 19, 2014. |
| EP11772624.0 Search Report dated Jun. 5, 2014. |
| EP09798764.8 Office Action dated Jun. 30, 2014. |
| Ettmayer et al. Lessons learned from marketed and investigational prodrugs. J Med Chem. 47(10):2393-404 (2004). |
| Fibbi et al., “Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.” Int J Androl. 33(3):475-88 (2010). |
| Fleischmann et al., “High Expression of Gastrin-Releasing Peptide Receptors in the Vascular bed of Urinary Tract Cancers: Promising Candidates for Vascular Targeting Applications.” Endocr. Relat. Cancer 16(2):623-33 (2009). |
| Froehlich et al., “Conscious sedation for gastroscopy: patient tolerance and cardiorespiratory parameters,” Gastroenterology 108(3):697-704 (1995). |
| Fujiwara et al., “Insulin-like growth factor 1 treatment via hydrogels rescues cochlear hair cells from ischemic injury.” NeuroReport 19(16):1585-1588 (2008). |
| Fulton et al. Thin Fluoropolymer films and nanoparticle coatings from the rapid expansion of supercritical carbon dioxide solutions with electrostatic collection, Polymer Communication. 2627-3632 (2003). |
| Green et al., “Simple conjugated polymer nanoparticles as biological labels,” Proc Roy Soc A. published online Jun. 24, 2009 doi:10.1098/rspa.2009.0181. |
| Griebenow et al., “On Protein Denaturation in Aqueous-Organic Mixtures but not in Pure Organic Solvents,” J. Am Chem Soc., vol. 118. No. 47, 11695-11700 (1996). |
| Hamilos et al., “Differential effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary Vasomotion.” JACC vol. 51, No. 22, Endothelium and DES, 2123-9 (2008). |
| Han, et al., “Studies of a Novel Human Thrombomodulin Immobilized Substrate: Surface Characterization and Anticoagulation Activity Evaluation.” J. Biomater. Sci. Polymer Edn, 12 (10):1075-1089 (2001). |
| Hartmann et al., “Tubo-ovarian abscess in virginal adolescents: exposure of the underlying etiology,” J. Pediatr Adolesc Gynecol, 22(3):313-16 (2009). |
| Hasegawa et al., “Nylong 6/Na-montmorillonite nanocomposites prepared by compounding Nylon 6 with Na-montmorillonite slurry,” Polymer 44:2933-2937 (2003). |
| Hinds, WC. Aerosol Technology, Properties, Behavior and Measurement of Airborne Particles, Department of Environmental Health Sciences, Harvard University School of Public Health, Boston, Massachusetts. 1982; 283-314. |
| Hladik et al., “Can a topical microbicide prevent rectal HIV transmission?” PLoS Med. 5(8):e167 (2008). |
| Iconomidou et al., “Secondary Structure of Chorion Proteins of the Teleosatan Fish Dentex dentex by ATR FR-IR and FT-Raman Spectroscopy,” J. of Structural Biology, 132, 112-122 (2000). |
| ID—W00201003529 Office Action dated Apr. 28, 2014. |
| IL—208648 Official Notification dated Feb. 9, 2012. |
| IL—201550 Official Notification dated Dec. 8, 2013. |
| IL—202321 Office Notification dated Dec. 19, 2013. |
| IN—368/DELNP/2008 Exam Report dated Oct. 17, 2011. |
| IN—6884/DELNP/2009 Office Action dated Oct. 31, 2013. |
| IN—7740/DELNP/2009 Office Action dated Jul. 29, 2014. |
| Jackson et al., “Characterization of perivascular poly(lactic-co-glycolic acid) films containing paclitaxel” Int. J. of Pharmaceutics, 283:97-109 (2004). |
| Jensen et al., Neointimal hyperplasia after sirollmus-eluting and paclitaxel-eluting stend implantation in diabetic patients: the randomized diabetes and drug eluting stent (DiabeDES) intravascular ultrasound trial. European heart journal (29), pp. 2733-2741. Oct. 2, 2008. Retrieved from the Internet. Retrieved on [Jul. 17, 2012]. URL:<http://eurheartj.oxfordjournals.org/content/29/22/2733.full.pdf> entire document. |
| Jewell, et al., “Release of Plasmid DNA from Intravascular Stents Coated with Ultrathin Multilayered Polyelectrolyte Films” Biomacromolecules. 7: 2483-2491 (2006). |
| Johns, H.E, J.R.Cunningham, Thomas, Charles C., Publisher, “The Physics of Radiology,” Springfield, IL, pp. 133-143 (1983). |
| Joner et al. “Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma,” Arterioscler Thromb Vasc Biol. 28:1960-1966 (2008). |
| Jovanovic et al. “Stabilization of Proteins in Dry Powder Formulations Using Supercritical Fluid Technology,” Pharm. Res. 21(11), (2004). |
| JP 2008-521633 Office Action dated Oct. 12, 2012. |
| JP2008-521633 Office Action dated Dec. 28, 2011. |
| JP-2009-534823 Office Action dated Apr. 23, 2013. |
| JP-2009-534823 Office Action dated Feb. 21, 2012. |
| JP-2009-534823 Office Action dated Sep. 20, 2012. |
| JP-2009-545647 Office Action dated Jun. 5, 2012. |
| JP-2009-545647 Office Action dated May 14, 2013. |
| JP-2009-545647 Office Action dated Apr. 22, 2014. |
| JP-2010-504253 Office Action dated Dec. 12, 2011. |
| JP-2010-504253 Office Action dated Dec. 7, 2012. |
| JP-2010-510441 Office Action dated May 7, 2013. |
| JP-2011-505248 Office Action dated Jun. 4, 2013. |
| JP-2011-518920 Office Action dated Dec. 17, 2012. |
| JP-2011-518920 Office Action dated Oct. 23, 2013. |
| JP-2012-503677 Office Action dated Jan. 18, 2013. |
| JP-2012-503677 Office Action dated Nov. 1, 2013. |
| JP-2012-151964 Office Action dated Dec. 10, 2013. |
| JP-2013-024508 Office Action dated May 2, 2014. |
| JP-2013-190903 Office Action dated Sep. 2, 2014. |
| Kazemi et al., “The effect of betamethasone gel in reducing sore throat, cough, and hoarseness after laryngo-tracheal intubation,” Middle East J. Anesthesiol. 19(1):197-204 (2007). |
| Kehinde et al., “Bacteriology of urinary tract infection associated with indwelling J ureteral stents,” J. Endourol. 18(9):891-896 (2004). |
| Kelly et al., “Double-balloon trapping technique for embolization of a large wide-necked superior cerebellar artery aneurysm: case report,” Neurosurgery 63(4 Suppl 2):291-292 (2008). |
| Khan et al., “Chemistry and the new uses of Sucrose: How Important?” Pur and Appl. Chem 56:833-844 (1984). |
| Khan et al., “Cyclic Acetals of 4,1′,6′-Trichloro-4,1′,6′,-Trideoxy- Trideoxy-galacto-Sucrose and their Conversion into Methyl Ether Derivatives.” Carb. Res. 198:275-283 (1990). |
| Khan et al., “Enzymic Regioselective Hydrolysis of Peracetylated Reducing Disaccharides, Specifically at the Anomeric Centre: Intermediates for the Synthesis of Oligosaccharides.” Tetrahedron Letters 34:7767 (1933). |
| Khayankarn et al., “Adhesion and Permeability of Polyimide-Clay Nanocomposite Films for Protective Coatings,” Journal of Applied Polymer Science, vol. 89, 2875-2881 (2003). |
| Koh et al., A novel nanostructured poly(lactic-co-glycolic-acid)-multi-walled carbon nanotube composite for blood-contacting applications: Thrombogenicity studies, Acta Biomaterialia 5:3411-3422 (2009). |
| KR10-2008-7003756 Office Action dated Sep. 23, 2013. |
| KR10-2008-7003756 Office Action dated Oct. 30, 2012. |
| KR 10-2013-7031237 Office Action dated Mar. 17, 2014. |
| Kurt et al., “Tandem oral, rectal and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability,” Am J. Emerg. Med. 27(5):631, e1-2 (2009). |
| Labhasetwar et al., “Arterial uptake of biodegradable nanoparticles: effect of surface modifications,” Journal of Pharmaceutical Sciences, vol. 87, No. 10, 1229-1234 (1998). |
| Lamm et al., “Bladder Cancer: Current Optimal Intravesical Treatment: Pharmacologic Treatment,” Urologic Nursing 25(5):323-6, 331-2 (Oct. 26, 2005). |
| Latella et al., “Nanoindentation hardness. Young's modulus, and creep behavior of organic-inorganic silica-based sol-gel thin films on copper,” J Mater Res 23(9): 2357-2365 (2008). |
| Lawrence et al., “Rectal tacrolimus in the treatment of resistant ulcerative proctitis,” Aliment. Pharmacol Ther. 28(10):1214-20 (2008). |
| Lee et al., “Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel,”Otol. Neurotol. 28(7):976-81 (2007). |
| Lehmann et al, “Drug treatment of nonviral sexually transmitted diseases: specific issues in adolescents,” Pediatr Drugs 3(7):481-494 (2001). |
| Mahoney et al., “Three-Dimensional Compositional Analysis of Drug Eluting Stent Coatings Using Cluster Secondary Ion mass Spectrometry,” Anal. Chem. 80:624-632 (2008). |
| Mario, C.D. et al., “Drug-Eluting Bioabsorbable Magnesium Stent,” J. Interventional Cardiology 16(6):391-395 (2004). |
| Matsumoto, D, et al. Neointimal Coverage of Sirolimus-Eluting Stents at 6-month Follow-up: Evaluated by Optical Coherence Tomography, European Heart Journal, 28:961-967 (2006). |
| McAlpine, J.B. et al., “Revised NMR Assignments for Rapamycine,” J. Antibiotics 44:688-690 (1991). |
| Mehik et al., “Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospecitve, randomized, double-blind, placebo-controlled, pilot study,” Urology 62(3):425-429 (2003). |
| Mei et al., “Local Delivery of Modified Paclitaxel-Loaded Poly( ε-caprolactone)/Pluronic F68 Nanoparticles for Long-Term Inhibition of Hyperplasia,” Journal of Pharmaceutical Sciences, vol. 98, No. 6, (Jun. 2009). |
| Melonakos et al., Treatment of low-grade bulbar transitional cell carcinoma with urethral instillation of mitomycin C, Adv. Urol., 173694 Epub; (2008). |
| Merrett et al., “Interaction of corneal cells with transforming growth factor beta2-modified poly dimethyl siloxane surfaces,” Journal of Biomedical Materials Research, Part A, vol. 67A, No. 3, pp. 981-993 (2003). |
| Merriam-Webster Online Dictionary, obtained online at: http://www.merriam-webster.com/dictionary/derivative, downloaded Jan. 23, 2013. |
| Middleton and Tipton, Synthetic biodegradable polymers as orthopedic devises. Biomaterials 21:2335-46 (2000). |
| Minchin, “Nanomedicine: sizing up targets with nanoparticles,” Nature Nanotechnology, 33:12-13 (2008). |
| Minoque et al., “Laryngotracheal topicalization with lidocaine before intubation decreases the incidence of coughing on emergence from general anesthesia,” Anesth. Analg. 99(4):1253-1257 (2004). |
| Mishima et al. “Microencapsulation of Proteins by Rapid Expansion of Supercritical Solution with a Nonsolvent,” AlChE J. 46(4):857-65 (2000). |
| Mocco et al., “Pharos neurovascular intracranail stent: Elective use for a symptomatic stenosis refractory to medical therapy,” Catheter Cardiovasc. Interv. (epub) (Mar. 2009). |
| Mollen et al., “Prevalence of tubo-ovarian abcess in adolescents diagnosed with pelvice inflammatory disease in a pediatric emergency department,” Pediatr. Emerg. Care, 22(9): 621-625 (2006). |
| Moroni et al., “Post-ischemic brain damage:targeting PARP-1 within the ischemic neurovaschular units as a realistic avenue to stroke treatment,” FEBS J. 276(1):36-45 (2009). |
| Muhlen et al., “Magnetic Resonance Imaging Contrast Agent Targeted Toward Activated Platelets Allows in Vivo Detection of Thrombosis and Monitoring of Thrombolysis Circulation,” 118:258-267 (2008). |
| Murphy et al., “Chronic prostatitis: management strategies,” Drugs 69(1): 71-84 (2009). |
| MX/a/2010/01148 Office Action dated Feb. 11, 2014. |
| NZ 588549 Examination Report dated Mar. 28, 2011. |
| NZ 600814 Examination Report dated Jun. 29, 2012. |
| O'Neil et al., “Extracellular matrix binding mixed micelles for drug delivery applications,” Journal of Controlled Release 137:146-151 (2009). |
| O'Donnell et al., “Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin alone perviously failed,” Jour. Urology, 166(4):1300-1304 (2001). |
| Olbert et al., “In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall,” Anticancer Res. 29(6):2067-2076 (2009). |
| Ong and Serruys, “Technology Insight: an overview of research in drug-eluting stents,” Nat. Clin. Perot. Cardiovas. Med. 2(12):647-658 (2005). |
| PCT/US06/24221 International Preliminary Report on Patentability mailed Dec. 24, 2007. |
| PCT/US06/24221 International Search Report mailed Jan. 29, 2007. |
| PCT/US06/27321 International Preliminary Report on Patentability mailed Jan. 16, 2008. |
| PCT/US06/27321 International Search Report mailed Oct. 16, 2007. |
| PCT/US06/27322 International Preliminary Report on Patentability mailed Jan. 16, 2008. |
| PCT/US06/27322 International Search Report mailed Apr. 25, 2007. |
| PCT/US07/10227 International Preliminary Report on Patentability mailed Oct. 28, 2008. |
| PCT/US07/10227 International Search Report mailed Aug. 8, 2008. |
| PCT/US07/80213 International Preliminary Report on Patentability mailed Apr. 7, 2009. |
| PCT/US07/80213 International Search Report mailed Apr. 16, 2008. |
| PCT/US07/82275 International Search Report mailed Apr. 18, 2008. |
| PCT/US07/82775 International Preliminary Report on Patentablity mailed Apr. 28, 2009. |
| PCT/US08/11852 International Preliminary Report on Patentability mailed Apr. 20, 2010. |
| PCT/US08/11852 International Search Report mailed Dec. 19, 2008. |
| PCT/US08/50536 International Preliminary Report on Patentability mailed Jul. 14, 2009. |
| PCT/US08/50536 International Search Report mailed Jun. 2, 2008. |
| PCT/US08/60671 International Preliminary Report on Patentability mailed Oct. 20, 2009. |
| PCT/US08/60671 International Search Report mailed Sep. 5, 2008. |
| PCT/US08/64732 International Preliminary Report on Patentability mailed Dec. 1, 2009. |
| PCT/US08/64732 International Search Report mailed Sep. 4, 2008. |
| PCT/US09/41045 International Preliminary Report on Patentability mailed Oct. 19, 2010. |
| PCT/US09/41045 International Search Report mailed Aug. 11, 2009. |
| PCT/US09/50883 International Preliminary Report on Patentability mailed Jan. 18, 2011. |
| PCT/US09/50883 International Search Report mailed Nov. 17, 2009. |
| PCT/US09/69603 International Preliminary Report on Patentability mailed Jun. 29, 2011. |
| PCT/US09/69603 International Search Report mailed Nov. 5, 2010. |
| PCT/US10/28195 International Preliminary Report on Patentability mailed Sep. 27, 2011. |
| PCT/US10/28195 Search Report and Written Opinion mailed Jan. 21, 2011. |
| PCT/US10/28253 International Preliminary Report on Patentability mailed Sep. 27, 2011. |
| PCT/US10/28253 Search Report and Written Opinion mailed Dec. 6, 2010. |
| PCT/US10/28265 International Report on Patentability mailed Sep. 27, 2011. |
| PCT/US10/28265 Search Report and Written Opinion mailed Dec. 3, 2010. |
| PCT/US10/29494 International Preliminary Report on Patentability mailed Oct. 4, 2011. |
| PCT/US10/29494 Search Report and Written Opinion mailed Feb. 7, 2011. |
| PCT/US10/31470 International Preliminary Report on Patentability mailed Oct. 18, 2011. |
| PCT/US10/31470 Search Report and Written Opinion mailed Jan. 28, 2011. |
| PCT/US10/42355 International Preliminary Report on Patentability mailed Jan. 17, 2012. |
| PCT/US10/42355 Search Report mailed Sep. 2, 2010. |
| PCT/US11/032371 International Report on Patentability mailed Oct. 16, 2012. |
| PCT/US11/032371 International Search Report mailed Jul. 7, 2011. |
| PCT/US11/044263 International Search Report, International Preliminary Report on Patentability and Written Opinion mailed Feb. 9, 2012. |
| PCT/US11/051092 International Preliminary Report on Patentability mailed Mar. 21, 2013. |
| PCT/US11/051092 International Search Report mailed Mar. 27, 2012. |
| PCT/US11/051092 Written Opinion mailed Mar. 27, 2012. |
| PCT/US11/22623 International Preliminary Report on Patentability mailed Aug. 7, 2012. |
| PCT/US11/22623 Search Report and Written Opinion mailed Mar. 28, 2011. |
| PCT/US11/29667 International Search Report and Written Opinion mailed Jun. 1, 2011. |
| PCT/US11/67921 International Preliminary Report on Patentability mailed Jul. 11, 2013. |
| PCT/US11/67921 Search Report and Written Opinion mailed Jun. 22, 2012. |
| PCT/US12/040040 International Search Report mailed Sep. 7, 2012. |
| PCT/US12/33367 International Preliminary Report on Patentability mailed Oct. 15, 2013. |
| PCT/US12/33367 International Search Report mailed Aug. 1, 2012. |
| PCT/US12/46545 International Search Report mailed Nov. 20, 2012. |
| PCT/US12/50408 International Search Report mailed Oct. 16 2012. |
| PCT/US13/41466 International Search Report and Written Opinion mailed Oct. 17, 2013. |
| PCT/US13/42093 International Search Report and Written Opinion mailed Oct. 24, 2013. |
| PCT/US2011/033225 International Search Report and Written Opinion mailed Jul. 7, 2011. |
| PCT/US2012/60896 International Search Report and Written Opinion mailed Dec. 28, 2012. |
| PCT/US2013/065777 International Search Report and Written Opinion mailed Jan. 29, 2014. |
| PCT/US2014/025017 International Search Report and Written Opinion mailed Jul. 7, 2014. |
| Perry et al., Chemical Engineers Handbook, 5th Edition, McGraw-Hill, New York, p. 20-106 (1973). |
| Plas et al., “Tubers and tumors: rapamycin therapy for benign and malignant tumors”, Curr Opin Cell Bio 21: 230-236, (2009). |
| Poling et al., The Properties of Gases and Liquids. McGraw-Hill. 9:1-9.97 (2001). |
| Pontari, “Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment,” Drugs Aging 20(15):1111-1115 (2003). |
| Pontari, “Inflammation and anti-inflammatory therapy in chronic prostatits,” Urology 60(6Suppl):29-33 (2002). |
| Putkisto, K. et al. “Polymer Coating of Paper Using Dry Surface Treatment—Coating Structure and Performance”, ePlace newsletter, vol. 1, No. 8, pp. 1-20 (2004). |
| Raganath et al., “Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour,” Pharm Res (Epub) (Jun. 20, 2009). |
| Ranade et al., “Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent,” J. Biomed Mater. Res. 71(4):625-634 (2004). |
| Reddy et al., “Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery,” Circ Cardiovasc Intery 1:209-216 (2008). |
| Ristikankare et al., “Sedation, topical pharnygeal anesthesia and cardiorespiratory safety during gastroscopy,” J. Clin Gastorenterol. 40(1):899-905 (2006). |
| Sahajanand, Medical Technologies (Supralimus Core; Jul. 6, 2008). |
| Salo et al., “Biofilm formation by Escherichia coli isolated from patients with urinary tract infections,” Clin Nephrol. 71(5):501-507 (2009). |
| Saxena et al., “Haemodialysis catheter-related bloodstream infections: current treatment options and strategies for prevention,” Swiss Med Wkly 135:127-138 (2005). |
| Schetsky, L. McDonald, “Shape Memory Alloys”, Encyclopedia of Chemical Technology (3d Ed), John Wiley & Sons 20:726-736 (1982). |
| Scheuffler et al., “Crystal Structure of Human Bone Morphogenetic Protein-2 at 2.7 Angstrom resolution,” Journal of Molecular Biology, vol. 287, Issue 1, Mar. 1999, retrieved online at http://wvwv.sciencedirect.com/science/article/pii/S002283699925901. |
| Schmidt et al., “A Comparison of the Mechanical Performance Characteristics of Seven Drug-Eluting Stent Systems,” Catheterization and Cardiovascular Interventions 73:350-360 (2009). |
| Schmidt et al., “In vitro measurement of quality parameters of stent-catheter systems,” Biomed Techn 50(S1):1505-1506 (2005). |
| Schmidt et al., “New aspects of in vitro testing of arterial stents based on the new European standard,” EN 14299, [online] (2009), [retrieved on Mar. 10, 2001] http://www.lib0ev.de/pl/pdf/EN14299.pdf (2009). |
| Schmidt et al., “Trackability, Crossability, and Pushability of Coronary Stent Systems—An Experimental Approach,” Biomed Techn 47:Erg. 1, S. 124-126 (2002). |
| Schreiber, S.L. et al., “Atomic Structure of the Rapamycin Human Immunophilin FKBP-12 Complex,” J. Am. Chem. Soc. 113:7433-7435 (1991). |
| Sen et al., “Topical heparin: A promising agent for the prevention of tracheal stenosis in airway surgery,” J. Surg. Res (Epub ahead of print) (Feb. 21, 2009). |
| Serruys, Patrick et al., Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel Disease, N. Engl. J. Med., vol. 344, No. 15, pp. 1117-1124 (2001). |
| SG201007602-4 Examination Report dated Feb. 13, 2013. |
| SG201007602-4 Written Opinion dated May 25, 2012. |
| Shekunov et al. “Crystallization Processes in Pharmaceutical Technology and Drug Delivery Design.” Journal of Crystal Growth 211:122-136 (2000). |
| Simpson et al., “Hyaluronan and hyaluronidase in genitourinary tumors.” Front Biosci. 13:5664-5680 (2009). |
| Smith et al., “Mitomycin C and the endoscopic treatment of laryngotracheal stenosis: are two applications better than one?” Laryngoscope 119(2):272-283 (2009). |
| Sumathi et al., “Controlled comparison between betamethasone gel and lidocaine jelly applied over tracheal tube to reduce postoperative sore throat, cough, and hoarseness of voice,” Br. J. Anaesth. 100(2):215-218 (2008). |
| Szabadits et al., “Flexibility and trackability of laser cut coronary stent systems,” Acta Bioengineering and Biomechanics 11(3):11-18 (2009). |
| Testa, B. Prodrug research: futile or fertile? Biochem Pharmacol. 1:68(11):2097-106 (2004). |
| Thalmann et al., “Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery,” J Urol. 168(4 Pt 1):1381-1385 (2002). |
| Torchlin, “Micellar Nanocarriers: Pharmaecutial Perspectives,” Pharmaceutical Research, vol. 24, No. 1, 17 pages. (2007). |
| U.S. Appl. No. 11/158,724 Office Action Mailed Dec. 31, 2013. |
| U.S. Appl. No. 11/158,724 Office Action Mailed May 23, 2013. |
| U.S. Appl. No. 11/158,724 Office Action Mailed Sep. 17, 2009. |
| U.S. Appl. No. 11/158,724 Office Action Mailed Sep. 26, 2012. |
| U.S. Appl. No. 11/158,724 Office Action Mailed Sep. 8, 2008. |
| U.S. Appl. No. 11/158,724 Office Action Mailed Jun. 25, 2014. |
| U.S. Appl. No. 11/877,591 Final Office Action Mailed Nov. 4, 2013. |
| U.S. Appl. No. 11/877,591 Office Action Mailed Feb. 29, 2012. |
| U.S. Appl. No. 11/877,591 Office Action Mailed Jul. 1, 2013. |
| U.S. Appl. No. 11/877,591 Office Action Mailed Sep. 21, 2012. |
| U.S. Appl. No. 11/877,591 Office Action Mailed May 7, 2014. |
| U.S. Appl. No. 11/995,685 Office Action Mailed Aug. 20, 2010. |
| U.S. Appl. No. 11/995,685 Office Action Mailed Nov. 24, 2009. |
| U.S. Appl. No. 11/995,687 Office Action Mailed Apr. 6, 2012. |
| U.S. Appl. No. 11/995,687 Office Action Mailed Sep. 28, 2011. |
| U.S. Appl. No. 12/298,459 Office Action Mailed Apr. 6, 2012. |
| U.S. Appl. No. 12/298,459 Office Action Mailed Aug. 10, 2011. |
| U.S. Appl. No. 12/298,459 Office Action Mailed May 31, 2013. |
| U.S. Appl. No. 12/426,198 Office Action Mailed Feb. 6, 2012. |
| U.S. Appl. No. 12/426,198 Office Action Mailed Feb. 7, 2014. |
| U.S. Appl. No. 12/426,198 Office Action Mailed Mar. 23, 2011. |
| U.S. Appl. No. 12/443,959 Office Action Mailed Dec. 13, 2012. |
| U.S. Appl. No. 12/443,959 Office Action Mailed Feb. 15, 2012. |
| U.S. Appl. No. 12/504,597 Final Office Action Mailed Oct. 3, 2012. |
| U.S. Appl. No. 12/504,597 Office Action Mailed Apr. 1, 2014. |
| U.S. Appl. No. 12/504,597 Office Action Mailed Dec. 5, 2011. |
| U.S. Appl. No. 12/522,379 Office Action Mailed Apr. 8, 2014. |
| U.S. Appl. No. 12/522,379 Final Office Action Mailed Aug. 28, 2013. |
| U.S. Appl. No. 12/522,379 Office Action Mailed Dec. 26, 2012. |
| U.S. Appl. No. 12/595,848 Office Action Mailed Jan. 13, 2012. |
| U.S. Appl. No. 12/595,848 Office Action Mailed Mar. 15, 2013. |
| U.S. Appl. No. 12/595,848 Office Action Mailed Oct. 22, 2013. |
| U.S. Appl. No. 12/595,848 Office Action Mailed Jun. 3, 2014. |
| U.S. Appl. No. 12/601,101 Office Action Mailed Dec. 27, 2012. |
| U.S. Appl. No. 12/601,101 Office Action Mailed Feb. 13, 2014. |
| U.S. Appl. No. 12/601,101 Office Action Mailed Mar. 27, 2012. |
| U.S. Appl. No. 12/601,101 Office Action Mailed May 22, 2013. |
| U.S. Appl. No. 12/648,106 Final Office Action Mailed Sep. 25, 2012. |
| U.S. Appl. No. 12/648,106 Office Action Mailed Jan. 30, 2012. |
| U.S. Appl. No. 12/648,106 Office Action Mailed Sep. 18, 2013. |
| U.S. Appl. No. 12/729,156 Final Office Action Mailed Oct. 16, 2012. |
| U.S. Appl. No. 12/729,156 Office Action Mailed Feb. 1, 2012. |
| U.S. Appl. No. 12/729,156 Office Action Mailed Feb. 13, 2014. |
| U.S. Appl. No. 12/729,156 Office action Mailed May 8, 2013. |
| U.S. Appl. No. 12/729,580 Final Office Action Mailed Nov. 14, 2013. |
| U.S. Appl. No. 12/729,580 Office Action Mailed Apr. 10, 2012. |
| U.S. Appl. No. 12/729,580 Office Action Mailed Jan. 22, 2013. |
| U.S. Appl. No. 12/729,580 Office Action Mailed Sep. 10, 2014. |
| U.S. Appl. No. 12/729,603 Final Office Action Mailed Oct. 10, 2012. |
| U.S. Appl. No. 12/729,603 Office Action Mailed Mar. 27, 2012. |
| U.S. Appl. No. 12/729,603 Office Action Mailed Jun. 25, 2014. |
| U.S. Appl. No. 12/738,411 Final Office Action Mailed Apr. 11, 2013. |
| U.S. Appl. No. 12/738,411 Office Action Mailed Aug. 21, 2013. |
| U.S. Appl. No. 12/738,411 Office Action Mailed Feb. 6, 2014. |
| U.S. Appl. No. 12/738,411 Office Action Mailed May 30, 2014. |
| U.S. Appl. No. 12/748,134 Office Action Mailed Jul. 18, 2013. |
| U.S. Appl. No. 12/751,902 Office Action Mailed Dec. 19, 2013. |
| U.S. Appl. No. 12/751,902 Office Action Mailed Jul. 13, 2012. |
| U.S. Appl. No. 12/762,007 Final Office Action Mailed Oct. 22, 2013. |
| U.S. Appl. No. 12/762,007 Final Office Action Mailed Apr. 30, 2014. |
| U.S. Appl. No. 12/762,007 Office Action Mailed Feb. 11, 2013. |
| U.S. Appl. No. 13/014,632 Office Action Mailed Jan. 10, 2014. |
| U.S. Appl. No. 13/014,632 Office Action Mailed May 8, 2013. |
| U.S. Appl. No. 13/086,335 Office Action Mailed May 22, 2013. |
| U.S. Appl. No. 13/086,335 Office Action Mailed Apr. 4, 2014. |
| U.S. Appl. No. 13/229,473 Office Action Mailed Jun. 17, 2013. |
| U.S. Appl. No. 13/340,472 Office Action Mailed Apr. 26, 2013. |
| U.S. Appl. No. 13/340,472 Office Action Mailed Jan. 15, 2014. |
| U.S. Appl. No. 13/340,472 Office Action Mailed Aug. 29, 2014. |
| U.S. Appl. No. 13/384,216 Final Action Mailed Nov. 6, 2013. |
| U.S. Appl. No. 13/384,216 Office Action Mailed Apr. 24, 2013. |
| U.S. Appl. No. 13/605,904 Office Action Mailed Jun. 28, 2013. |
| U.S. Appl. No. 13/605,904 Office Action Mailed Nov. 27, 2012. |
| U.S. Appl. No. 13/445,723 Office Action Mailed Mar. 14, 2014. |
| U.S. Appl. No. 13/090,525 Office Action Mailed Apr. 11, 2014. |
| U.S. Appl. No. 11/995,685 Office Action Mailed Jun. 18, 2014. |
| Unger et al., “Poly(ethylene carbonate): A thermoelastic and biodegradable biomaterial for drug eluting stent coatings?” Journal of Controlled Release, vol. 117, Issue 3, 312-321 (2007). |
| Verma et al., “Effect of surface properties on nanoparticle-cell interactions,” Small 6(1):12-21 (2010). |
| Wagenlehner et al., “A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis/chronic pelvic pain syndrome: a multicentre, randomized, prospective, double-blind, placebo-controlled phase 3 study,” Eur Urol 9 (Epub) (Jun. 3, 2009). |
| Wang et al. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials 27:5588-95 (2000). |
| Wang et al., “Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury,” Exp. Neurol 213(1):171-175 (2008). |
| Warner et al., “Mitomycin C and airway surgery: how well does it work?” Ontolaryngol Head Neck Surg. 138(6):700-709 (2008). |
| Wermuth, CG Similarity in drugs: reflections on analogue design. Drug Discov Today. 11(7-8):348-54. (2006). |
| Witjes et al., “Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results,” Eur. Urol. 53(1):45-52 (2008). |
| Wu et al., “Study on the preparation and characterization of biodegradable polylactide/multi-walled carbon nanotubes nanocomposites.” Polymer 48: 4449-4458 (2007). |
| Xu et al., “Biodegradation of poly(l-lactide-co-glycolide tube stents in bile” Polymer Degradation and Stability. 93:811-817 (2008). |
| Xue et al., “Spray-as-you-go airway topical anesthesia in patients with a difficult airway: a randomized, double-blind comparison of 2% and 4% lidocaine,” Anesth. Analg. 108(2): 536-543 (2009). |
| Yepes et al., “Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic,” Trends Neurosci. 32(1):48-55 (2009). |
| Yousof et al., “Reveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunction and associated cell death during cerebral ischemia,” Brain Res. 1250:242-253 (2009). |
| Zhou et al. Synthesis and Characterization of Biodegradable Low Molecular Weight Aliphatic Polyesters and Their Use in Protein-Delivery Systems. J Appl Polym Sci 91:1848-56 (2004). |
| Zilberman et al., Drug-Eluting bioresorbable stents for various applications, Annu Rev Biomed Eng., 8:158-180 (2006). |
| The Properties of Gases and Liquids, 5th ed., McGraw-Hill, Chapter 9, pp. 9.1-9.51, 2001. |
| Akoh et al., “One-Stage Synthesis of Raffinose Fatty Acid Polyesters.”Journal Food Science (1987) 52:1570. |
| Albert et al., “Antibiotics for preventing recurrent urinary tract infection in nonpregnant women,”Cochrane Database System Rev. 3, CD001209 (2004). |
| Au et al., “Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial,” Journal of the National Cancer Institute, 93 (8 ), 597-604 (2001). |
| Bugay et al., “Raman Analysis of Pharmaceuticals,” in “Applications of Vibrational Spectroscopy in Pharmaceutical Research and Development,” Edited by Pivonka, D.E., Chalmers, J.M., Griffiths, P.R. (2007) Wiley and Sons. |
| Charging of Materials and Transport of Charged Particles (Wiley Encyclopedia of Electrical and Electronics Engineering, John G. Webster (Editor), vol. 7, 1999, John Wiley & Sons, Inc., pp. 20-24). |
| Klein et al., Viscosities of pure gases can vary by as much as a factor of 5 depending upon the gas type, Int. J. Refrigeration 20: 208-217, 1997. |
| PCT/US07/82775 International Preliminary Report on Patentablity dated May 5, 2009. |
| PCT/US11/44263 International Preliminary Report on Patentability dated Jan. 22, 2013. |
| Number | Date | Country | |
|---|---|---|---|
| 20150040827 A1 | Feb 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12748134 | Mar 2010 | US |
| Child | 14310960 | US |
